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Graft-versus-host disease (GvHD) is a severe complication occurring after hematopoietic 
stem cell transplantation (HSCT). It is caused by alloreactive T cells contained in the graft, 
and associated with severe morbidity and mortality. Glucocorticoids (GC) are the gold 
standard for first-line treatment of GvHD but once patients become steroid-refractory, they 
need to be treated with second-line therapies such as extracorporeal photopheresis (ECP). 
ECP is an immunomodulatory therapy currently used in the clinic for treating patients 
suffering acute GvHD (aGvHD) or chronic GvHD (cGvHD). During ECP therapy leukocytes 
from the patient are collected by apheresis procedure and treated with 8-methoxypsoralen 
(8-MOP) and ultraviolet light type-A (UV-A) generating apoptotic cells which are then 
reinfused into the patient. These apoptotic cells are taken up by myeloid dendritic cells 
(mDCs) and may lead to cross-tolerization of T cells. Whether ECP therapy could be 
modified by using leukocytes from healthy blood donors instead of the patient’s own cells has 
not yet been explored although this option would offer the possibility to avoid the exhausting 
apheresis procedure.  
In this study, established mouse models of aGvHD (C57BL/6->BALB/c) and cGvHD (B10D2-
>BALB/c) were used to evaluate the effects of 8-MOP/UV-A (PUVA)-treated splenocytes 
derived from healthy genetically different mouse strains. ECP therapy using C3H mice as 
donors of splenocytes had a significant therapeutic effect on the course and severity of 
aGvHD whereas this was not the case for splenocytes with BALB/c and C57BL/6 origin. ECP 
therapy of cGvHD was successful when apoptotic splenocytes from B10D2 were used. Flow 
cytometric analysis did not reveal any cellular signature of cGvHD. Overall, the obtained 
results suggest that the therapeutic effect of ECP therapy might be achieved when there are 
extensive disparities in the human leukocyte antigen (HLA) haplotype between ECP recipient 
and cell donors.  
In addition, efforts were made to identify biomarkers that could predict the risk to develop 
GvHD and the patient’s response to ECP therapy. Several potential biomarkers were 
analyzed in peripheral blood by flow cytometry or enzyme-linked immunosorbent assay 
(ELISA). Reference values were determined for each potential biomarker in healthy blood 
donors and compared to the values measured in patients suffering from hematological 
malignancies before HSCT and after engraftment and in cGvHD patients before as well as 
three and six months after initiation of ECP therapy. Dependent on the time points of blood 
sampling we found significant differences in the percentages or cell counts of regulatory T 
(Treg) cells, immature B cells, mDCs, soluble interleukin-2 receptor-α (sIL-2Rα), soluble 
tumor necrosis-factor receptor 1 (sTNF-R), and hepatocyte growth factor (HGF) between 




Taken together, the combination of GvHD mouse models and the analysis of patient material 
represent a promising strategy to optimize the clinical application of ECP therapy in the 







2.1. Graft-versus-host disease 
2.1.1. Hematopoietic stem cell transplantation 
Hematopoietic stem cells (HSCs) are pluripotent, able to self-renew, and give rise to a limited 
set of differentiated cells. Since these cells can be directly isolated from adult bone marrow 
(BM) and peripheral blood, HSCs are a very promising therapeutic tool. HSCT is a treatment 
for severe disorders of the hematopoietic system where HSCs are transferred from a healthy 
donor to a recipient suffering for instance from leukemia or lymphoma. If the donor and the 
recipient are the same person one speaks of an autologous HSCT, if both are distinct 
persons it is an allogeneic HSCT (Hołowiecki, 2008). 
HSCs can be isolated from the BM or cord blood. Alternatively, peripheral blood stem cells 
(PBSCs) may be used. The low cell content of HSCs in cord blood limits the usage of their 
transplantation to children. In the past, most HSCTs were performed with BM cells whereas 
nowadays peripheral blood is the preferred source of HSCs (Körbling and Freireich, 2011). 
To increase the concentration of PBSCs in peripheral blood, donors are treated with human 
granulocyte colony-stimulating factor to mobilize the HSCs from the BM to move into the 
periphery (Dale, 1998). 
Indications for allogeneic HSCT are various haematological malignancies such as acute 
lymphoblastic (ALL) or acute/-chronic myeloid leukemia (AML/CML), and Hodgkin’s or Non-
Hodgkin’s lymphoma. Furthermore immunodeficiencies like X-linked lymphoproliferative 
disease and Wiskott-Aldrich syndrome, severe combined immunodeficiency (SCID) and 
defective haematopoiesis like sickle cell disease or platelet disorders are indications for 
HSCT (Hołowiecki, 2008; Lankester et al., 2005). 
A prerequisit for allogeneic HSCT is that, donors should be either HLA identical or as similar 
as possible. The first allogeneic HSCT was performed in 1968 by Good and colleagues to 
cure an immunodeficient 5-month-old infant by transplanting BM cells and peripheral blood 
buffy coat cells from a histo-compatible donor (Gatti et al., 1968). As a first step in HSCT, 
patients have to be conditioned to eliminate malignant cells and to reduce the risk of graft 
rejection. The outcome of the HSCT is highly influenced by the intensity of pretransplant 
conditioning regimen. Based on the toxicity and immunologic consequences of the 
conditioning a reduced intensity is associated with higher graft rejection whereas increased 
intensity results in higher risk of developing GvHD (Hill et al., 1997; Truitt and Atasoylu, 
1991). Patients are conditioned with chemotherapy, often combined with radiotherapy and T 
cell-depleting antibodies. Next, a cellular graft from the donor enriched in HSCs and 
containing mature CD4+ and CD8+ T cells is infused into the preconditioned patient. Hereby 




boosted. However, mature CD4+ and CD8+ T cells in parallel are also known to induce GvHD 
(Shlomchik, 2007). 
 
2.1.2. Pathogenesis and symptoms of GvHD 
GvHD is a severe complication occuring after allogeneic HSCT that is associated with a high 
transplant-related morbidity and mortality (Pasquini et al., 2010). In 1966, Billingham 
postulated three criteria for the development of GvHD: 1. the host must be incapable of 
rejecting the transplanted cells; 2. transplantation antigens must differ between donor and 
host; 3. the graft must contain immunologically competent cells (Billingham, 1966). These 
immunocompetent cells have been identified as mature T cells and their number correlates 
with disease severity (Kernan et al., 1986; Korngold and Sprent, 1978). 
Originally, two forms of GvHD were definded based on the onset of disease. aGvHD is 
characterized by the occurrence of symptoms within the first 100 days after HSCT whereas 
cGvHD occurs at least 100 days after transplantation. However, nowadays a pathological 
classification of GvHD is thought to be more useful since symptoms of aGvHD can also 
occur later than 100 days post transplantation and additionally an overlap syndrome with 
characteristics of both forms exists (Filipovich et al., 2005; Griffith et al., 2008). The 
pathogenesis of aGvHD is characterized by tissue damage of organ such as skin, liver, the 
gastrointestinal (GI) tract, and mucosa. In most patients the first manifestation of aGvHD are 
in skin leading to a maculopapular rash, and/-or in the GI tract (Greinix et al., 2006a; Martin 
et al., 1990). If the GI tract is involved patients suffer from diarrhea, vomiting, anorexia, and 
abdominal pain (Ferrara and Deeg, 1991). GvHD involving the liver is characterized by bile 
duct damage and cholestatic hyperbilirubinemia (Ferrara et al., 2009; Snover et al., 1984). In 
cGvHD not only the organs affected in aGvHD are targets but also connective tissue and 
exocrine glands can be affected (Ramadan and Paczesny, 2015). However, compared to the 
acute form of GvHD the pathophysiology of cGvHD is poorly understood (Ferrara et al., 
2009). Ferrara and colleagues described three phases for the pathophysiology of aGvHD 
(Fig. 1). The first phase involves the activation of antigen-presenting cells (APCs) and is 
initiated by tissue damage caused by the underlying malignancy and/or the conditioning 
regimen. Damaged tissues and cells produce inflammatory cytokines such as tumor necrosis 
factor alpha (TNF-α), interleukin 1 (IL-1) and -6 (IL-6), and release of other “danger” signals 
such as damage-associated molecular patterns or pathogen-associated molecular patterns 
including lipopolysaccharide (LPS) from intestinal microbiota (Hill and Ferrara, 2000; 




In the second phase of GvHD, the interaction between donor T cells and host APCs leads to 
T cell activation followed by proliferation and differentiation of the T cells. Activation of these 
cells results in complex intracellular biochemical cascades leading to production of many pro-




Fig. 1: Schemati c overvie w of GvHD pathophysiol ogy.  
Fig. 1: Schematic overview of GvHD pathophysiology. (Reprinted from The Lancet, Vol. 373, 
James L M Ferrara, John E Levine, Pavan Reddy, Ernst Holler, Graft-versus-host disease, Pages No. 
1550-61, Copyright (2009), with permission from Elsevier.)  
 
In the third cellular and inflammatory effector phase the pathogenic T cells enter GvHD target 
organs and release additional effector molecules leading to further local tissue destruction. 
Cellular effector cells are mostly cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells 
(Ferrara et al., 2009). Apoptosis induction in liver is mainly caused by the cytolytic activity of 
CTLs via the Fas/FasL pathway whereas in the GI tract and skin the perforin/granzyme 
pathway dominates (Lowin et al., 1994; Schmaltz et al., 2001). Furthermore, migration of 




chemokines such as CCL2-5, CXCL2, CXCL9-11, CCL17 and CCL27 which respond to 
inflammatory stimuli such as TNF-α (Wysocki et al., 2005). Damaged skin or mucosa allow 
the infiltration of LPS and other microbial products and activate secretion of inflammatory 
cytokines (Hill and Ferrara, 2000). TNF-α is known to promote skin and gut lesions and has a 
variety of functions. First of all, it triggers APCs and hereby amplifies the presentation of 
alloantigens. Second, through activating effector cells it induces inflammatory chemokines to 
target specific organs, and third it damages tissues by necrosis (Brown et al., 2002; Hill et al., 
2000; Piguet et al., 1987). Based on all these functions of TNF-α, one would hypothesize that 
inhibition of TNF-α after HSCT would be an approach to foster the GvL effect while 
diminishing the risk of developing GvHD. However, it has been found that the p55 TNF-α 
receptor submits to GvL effect by impairing CTL activity after HSCT (Hill et al., 1999). 
Several risk factors for GvHD have been defined. The most important one is HLA disparity. 
Those patients receiving transplants from unrelated donors have a higher likelihood of 
developing GvHD and a worse overall outcome the greater the degree of the HLA-mismatch 
is (Beatty et al., 1985; Kernan et al., 1993; Szydlo et al., 1997). However, even if patients 
receive HLA-matched grafts they still can develop GvHD (Bortin et al., 1991). This is most 
likely due to disparities in minor histocompatibility antigens (miHAs) between donor and 
recipient (Goulmy et al., 1996; Martin, 1991). miHAs are polymorphic peptides which are 
presented by major histocompatibility antigens (MHC) class I or II molecules and can be 
recognized by T lymphocytes in the transplant. Disparities of miHAs can for instance be 
derived from gene deletions or amino acid polymorphism (Falkenburg et al., 2003). As 
mentioned above, PBSCs are the preferred source of HSCs these days. Interestingly, 
however meta analyses have shown that aGvHD is slighty increased in patients transplanted 
with PBSCs compared to BM transplants (Cutler et al., 2001). Additionally, the amounts of 
CD34+ cells in PBSC grafts is higher, which correlates with an increased likelihood to develop 
GvHD (Przepiorka et al., 1999). Furthermore, the probability of GvHD rises if recipient and 
donor are of older age (Weisdorf et al., 1991). The likelihood of developing aGvHD is also 
higher if recipient and donor are of different sex, especially if a male recipient received HSCs 
from a female donor (Flowers et al., 1990; OKunewick et al., 1993). Finally, the intensity of 
the conditioning regimen correlates with an increased tissue damage resulting in a higher 





2.1.3. Treatment of GvHD 
2.1.3.1. GvHD prophylaxis 
GvHD is a major complication after allogeneic HSCT but at the same time the GvL effect 
plays an important role in eradicating residual malignant cells. Therefore, GvHD prophylaxis 
is an important issue. After myeloablative conditioning a combination of immunosuppressant 
drugs such as the calcineurin inhibitor cyclosporin A (CsA) and low-dose methotrexate (MTX) 
is routinely administrated for prevention of aGvHD (Ruutu et al., 2014; Storb et al., 1988). 
CsA inhibits T cell activation by blocking the calcineurin/NFAT pathway as well as the Jun 
amino-terminal kinases (JNK) and p38 signaling pathways (Matsuda and Koyasu, 2000). The 
folate antagonist MTX is able to delete proliferating donor lymphocytes (Pavletic and Fowler, 
2012). Furthermore, another calcineurin inhibitor named tacrolimus (TAC) was tested in 
clinical trials and found to reduce the incidence of  aGvHD in patients receiving TAC/MTX 
combination therapy as compared to those administered CsA/MTX alone (Nash et al., 2000; 
Ratanatharathorn et al., 1998). Patients treated with a reduced intensity conditioning 
regularly receive a combination of CsA and mycophenolate mofetil (MMF). Via its metabolite 
mycophenolic acids, MMF inhibits proliferation of activated lymphocytes (Bornhäuser et al., 
1999). 
Although the administration of calcineurin inhibitors combined with MMF or MTX results in a 
good survival rate, many patients are still dying from GvHD. Since T cells play a key role in 
pathogenesis of GvHD several attempts to reduce T cell numbers with monoclonal 
antibodies were made to prevent GvHD. However, this attempt resulted in an increased risk 
of leukemia relapse, infections and graft failure (Antin, 2011). Another strategy regularly used 
in the clinics is the anti-thymocyte globulin (ATG) an in vivo used anti-Jurkat antibody. ATG 
recipients had significantly reduced aGvHD severity and additionally a reduced 3-year-
incidence of cGvHD (Socié et al., 2011). 
 
2.1.3.2. First-line treatment of GvHD 
Despite the standard use of preventive approaches many allogeneic transplanted patients 
are still diagnosed with GvHD. However, before GvHD treatment can be initiated the severity 
of the disease has to be graded according to the Keystone Consensus 1994 (Przepiorka et 
al., 1995) or the CIBMTR criteria (Rowlings et al., 1997). 
Until now, GC treatment is the standard first-line therapy for aGVHD. Except for aGvHD 
patients with upper GI tract involvement receiving 1 mg/kg per day, most aGvHD patients 
receive methylprednisolone at 2 mg/kg/day or prednisone at 2 to 2.5 mg/kg per day 




(Martin et al., 2012a). It is noteworthy that higher doses of corticosteroids of 10 mg/kg/day 
seem to have no advantage compared to the normal dose (Van Lint et al., 1998). On the 
other hand, in a retrospective study a reduced corticosteroid dose of 1 mg/kg/day resulted in 
no disadvantages as compared to the normal dose of 2 mg/kg/day (Mielcarek et al., 2009). 
GCs have broad anti-inflammatory, pro-apoptotic and immunosuppressive activity (Martin et 
al., 2009). Nonetheless, it has to be taken into account that the prolonged application of high-
dose GCs may come along with several side effects such as opportunistic infections, 
diabetes, or osteoporosis (Martin et al., 2012b; Martínez and Urbano-Ispízua, 2011). 
Several approaches were taken and failed to find a possibility to intensify the first-line 
treatment. As an example, the addition of antibodies against IL-2 (daclizumab) or TNF-α 
(infliximab) did not improve response rates (Couriel et al., 2009; Lee et al., 2004; Levine et 
al., 2008).  
The initial dose of the first-line treatment is administrated for five to ten days and is tapered 
slowly when patients respond. When patients do not respond to GC treatment or show 
progression of the disease, administration is continued and second-line treatment initiated 
(Martin et al., 2012a). 
Compared to aGvHD the chronic form of GvHD is generally treated with GCs often combined 
with CsA and TAC (Wolff et al., 2010). However the response to this treatment cannot be 
predicted and overall only 20 to 50% of cGvHD patients gain complete resolution of GvHD 
(Martin et al., 2009). It is noteworthy that it even may occur that organs respond differently in 
the same patient. 
 
2.1.3.3. Second-line treatment of GvHD 
In cases where GCs fail to sufficiently control GVHD, a second-line treatment needs to be 
initiated. Up to now specific guidelines for the administration of second-line treatment are not 
defined and differ among clinicians (Martin et al., 2012a). In 2012, Martin and colleagues 
compared several studies with possible agents for second-line treatment in GC-refractory 
aGvHD patients: antimetabolites, ECP, monoclonal antibodies against IL-2, TNF-α, CD52, 
and ATG. However, based on the overall survival and complete response rates they found 
no evidence that any of these therapies were better or worse than the other. In contrast, it 
was found a higher survival rate in patients suffering from GC-refractory grade II aGvHD 






2.2. Extracorporeal photopheresis therapy 
2.2.1. Apheresis procedure of ECP in clinics 
ECP combines two well-known treatment modalities in dermatology. The first modality 
“PUVA” is a combination of the light-sensitive agent 8-MOP and UV-A. The second modality 
is leukapheresis where nucleated cells are separated from patient’s blood.  
The first closed system of an instrument for ECP treatment was developed by Richard 
Edelson. It consisted of a large radiation chamber and a standard blood circulating system 
also used in dialysis. Since then, the photopheresis device was improved with regard to the 
efficacy of cell separation and handling, treatment time and applicability for low body weight 
patients. 
During the ECP procedure, whole blood is drawn from the patient and mechanically 
separated into plasma and cellular fractions. The mechanical separation is based on density 
centrifugation. Erythrocytes are directly returned to the patient whereas approximately 5-10% 
of the circulating mononuclear cells (MNCs) are collected and treated with 200 ng/ml 8-MOP. 
Afterwards these leukocytes are irradiated at 2 J/cm2 in an UV-A irradiator. During PUVA 
treatment 8-MOP quickly permeates the nuclear membrane and cross-links the 
deoxyribonucleic acid (DNA) leading to the induction of apoptosis in treated lymphoid cells, in 
particular natural killer and T cells (Wolnicka-Glubisz et al., 2010). Subsequently, these cells 
undergo cell death one to two days after reinfusion into the patient (Greinix et al., 2006a). 
ECP is recommended on two consecutive days (one cycle) per week until therapeutic 
response is achieved, and then tapered to alternate weeks before discontinuation (Das-
Gupta et al., 2014). 
Although ECP therapy is well tolerated and associated with minimal side effects, there are 
some limitations to this procedure. First of all, patients must have a good venous access for 
performing ECP therapy. Especially in patients with skin involvement the access may be 
difficult, which limits ECP performance. Furthermore, patients must be able to tolerate 
reinfusion of PUVA-treated MNCs and must be able to resist the sings of volumes during 
apheresis. Another rare but regularly occurring contraindication is an allergy against 8-MOP 
or heparin. Furthermore, patients with low numbers of white blood cells (<1x109 per liter) 
would probably not benefit from ECP therapy. (Greinix and Knobler, 2012) 
 
2.2.2. Potential mechanisms of action of ECP therapy 
Although ECP therapy has been used in the clinic for more than 30 years treating several 
diseases, the mechanism of action is yet poor understood. Some studies pointed out that the 




and Taylor, 1999; Gerber et al., 2000). In contrast to other immunosuppressive therapies 
ECP therapy induces immune tolerance by inhibiting alloantigen-responding T cells using 
apoptotic leukocytes (Marshall, 2006; McKenna et al., 2006). The immunmodulatory effect 
may include the modulation of dendritic cells (DCs), induction of T cell subpopulations and 
changes in cytokine levels (Goussetis et al., 2012; Voss et al., 2010). After ECP therapy 
monocytes seem to differentiate into immature DCs which subsequently, phagocytose 
apoptotic lymphocytes and present their antigenic peptides (Hannani et al., 2010; Spisek et 
al., 2006). This differentiation process is accompanied by secretion of various cytokines such 
as TNF-α and IL-6 and an activation of macrophages (Fimiani et al., 1997). Additionally, ECP 
therapy seems to increase the release of anti-inflammatory cytokines whereas pro-
inflammatory cytokines are reduced (Bladon and Taylor, 2006).   
In GvHD patients it was shown that ECP therapy modulates the arginine metabolism known 
to play a role in immune tolerance by upregulating IL-10 (Merlin et al., 2011). Furthermore 
ECP therapy also induces Treg cells suppressing the activity of other lymphocytes but 
without causing general immunosuppression (Maeda et al., 2005a, 2008a). Thus IL-10 is 
thought to be involved in these processes since it plays a role in Treg cells that inhibit the 
effector phase of GvHD (Maeda et al., 2008b). 
Up to now several research groups have studied the effect of ECP on Treg cells. Rezwani 
and colleagues found that allogeneic transplanted patients with low number of Treg cells 
have a higher risk of developing aGvHD (Rezvani et al., 2006; Wolf et al., 2007). Additionally, 





Fig. 2: Scheme of possibl e mode s of acti on of ECP treatment  
Fig. 2: Scheme of possible modes of action of ECP treatment. During GvHD, APCs phagocytose 
foreign antigens and present them to T cells. Subsequently, cytokines are secreted which start to 
stimulate CTL activity directed against foreign antigens. ECP therapy causes apoptosis in activated 
CTLs. After reinfusion of these apoptotic CTLs into the patient, APCs recognize apoptosis-specific 
proteins and start producing anti-inflammatory cytokines as well as promoting the development of Treg 
cells. (Reprinted from Journal of Clinical Apheresis, Vol. 26, David M. Ward, Extracorporeal 
photopheresis: How, when, and why, Pages No. 276-85, Copyright (2011), with permission from 
Wiley-Liss, Inc.)  
 
2.2.3. ECP therapy for the treatment of GvHD 
In 2000 BC Egyptian healers had treated patients suffering from a pigment disorder “vitiligo” 
with 8-MOP which was part of a boiled extract acquired from the weed Ammi majus and 
exposed them to natural sun light (Pathak and Fitzpatrick, 1992). Several millenniums and 
modifications later, Richard Edelson introduced ECP in 1981 as treatment of cutaneous T 
cell lymphoma (CTCL) (Edelson et al., 1987). In 1988, the FDA approved ECP as the first 
authorized cellular immunotherapy for any cancer (Worel and Leitner, 2012).  Based on the 
high efficacy of ECP in CTCL, the potential therapeutic effect of ECP was studied in other T 
cell mediated diseases as well, including systemic sclerosis (Rook et al., 1992), solid organ 
rejection (Barr et al., 1998; Costanzo-Nordin et al., 1992) and GvHD (Flowers et al., 2008; 
Greinix et al., 1998). 
ECP therapy is well tolerated and has minimal side effects (Hart et al., 2013). In comparison 




infections (Greinix et al., 2000). Several studies were performed to determine the therapeutic 
effect of ECP in GvHD patients. In a cohort of 59 aGVHD patients, ECP therapy led to a 
complete remission (CR) in 82%, 61% and 60% of patients, respectively having either 
cutaneous, liver or gut involvement (Greinix et al., 2006a). In addition, patients with only 
cutaneous symptoms had the highest CR rate (87%). Those where two organ systems were 
involved had lower CR rates (40-62%) and those with three organ systems involved had 
even lower CR rates (25%). Cutaneous cGVHD completely resolved in 80-92% of patients 
treated with ECP (Dignan et al., 2012; Greinix et al., 1998). 
 
2.3. Mouse models of GvHD and ECP 
Precise and reproducible mouse models of GvHD are crucial in advancing our understanding 
of the pathomechanism of GvHD in its acute and chronic forms. Mouse models are essential 
for finding new therapies or for modifying current treatment regimens aimed to increase their 
efficacy. The understanding of the biology of GvHD has largely been defined using mouse 
models. Korngold and colleagues found in 1978 that T cell alloreactivity is the underlying 
cause of both forms of GvHD (Korngold and Sprent, 1978; Sprent et al., 1986). In mice, both 
forms of GvHD have different phenotypes which mainly results from the differential 
involvement of CTLs or T helper (Th) cells (Schroeder and DiPersio, 2011a).  
The severity of aGvHD in mice depends on several factors. The conditioning of the recipient 
mice is usually performed by body irraditation and the dose correlates with the degree of 
tissue damage. The resulting cytokine storm is directly proportional to the mortality of the 
recipient mice (Hill et al., 1997; Schwarte and Hoffmann, 2005). Furthermore, the type, 
genetic source and dose of the T cell subsets in the graft can influence the severity and 
outcome of aGvHD (Korngold, 1992; Korngold and Sprent, 1978; Sprent et al., 1988). 
Another factor affecting the severity of aGvHD are the slight the differences between mice 
obtained from individual suppliers concerning environmental pathogens and genetic factors.  
There are several mouse models of aGvHD existing. The most commonly studied total MHC-
mismatch model of aGvHD involves the grafting of BM and T cells from the C57BL/6 mice 
into irradiated BALB/c recipient mice (C57BL/6->BALB/c). In this model both, CD8+ CTLs and 
CD4+ Th cells contribute to the phenotype (Sprent et al., 1990). CD8+ T cells are activated by 
recipient APCs via binding of the T cell receptor (TCR) to MHC class I peptide complexes 
leading to the release of perforin, granzymes and the expression of Fas ligand (Graubert et 
al., 1997; Maeda et al., 2005b; Shlomchik et al., 1999; Via et al., 1996). In contrast, CD4+ 
cells can be activated by donor or recipient APCs leading to a TNF-α-mediated cytotoxic 




Compared to aGvHD models, the induction of cGvHD in bone marrow transplantation (BMT) 
models using inbred mouse strains is difficult. The sclerodermatous (pro-fibrotic) cGvHD 
model is characterized by fibrotic damages in the dermis of lung, liver and salvary glands. 
The mostly studied scleroderma model is based on BALB/c mice receiving a B10.D2 graft 
(B10.D2->BALB/c) (Jaffee and Claman, 1983). This model is a MHC-match but miHA-
mismatch model of cGvHD with mainly CD4+ T cells contributing to its phenotype.  Recipient 
mice are irradiated sublethally and transplanted with BM cells and splenocytes. The 
development of fibrotic changes in cGvHD mouse model starts within 30 days after 
transplantation which is more rapid than in patients. (Schroeder and DiPersio, 2011) 
Gatza and co-workers transferred the clinically used human ECP setup into a MHC-matched 
but miHA-mismatched mouse model of aGvHD. They found that the conventional ECP had a 
therapeutic effect on aGvHD (Gatza et al., 2008). This finding was confirmed by Budde and 
colleagues who observed a therapeutic effect of conventional ECP in a total MHC-mismatch 
mouse model of aGvHD (Budde et al., 2014). 
 
2.4. GvHD biomarkers 
Biological markers also named biomarkers are molecular, biochemical or cellular alterations 
which can be measured in tissues, fluids and cells of species. Biomarkers help differentiating 
between normal or pathologic biological processes and can contribute to the understanding 
of disease causes or the prediction and response rates to treatment regimens (Naylor, 2003; 
Talbott and Craun, 1995). 
An ideal biomarker has to be non-invasively accessible. Its measurements should be precise, 
reproducible, and cost-effective. Furthermore, it should be able to measure the biomarkers 
with high specificity and sensitivity. Concerning GvHD, a biomarker should be able to 
differentiate between patients with and those without GvHD. Additionally the most valuable 
biomarker will be able to categorize the risk of each patient to develop GvHD in order to 
begin preventive therapies even before symptoms manifest. (Paczesny et al., 2013).  
With regard to GvHD, one looks for biomarkers that indicate the risk to develop GvHD after 
HSCT, the prognosis, and responsiveness to treatment. Several types of biomarkers are 
currently under investigation. In this context, cellular immunoregulatory and inflammatory 
biomarkers are discussed. In aGvHD and cGvHD there are various immune cell populations 
which are already thought to represent GvHD biomarkers.  
Amongst others, CD3+ T cells as well as CD4+ and CD8+ T cells levels are known to be 




In contrast, CD8+ cells are increased in aGvHD (August et al., 2011). Furthermore, immature 
B cells (CD19+ CD21-) were found to be elevated when comparing patients developing 
cGvHD and to those not suffering from cGvHD  (Greinix et al., 2008). 
 
mDCs are APCs that bind antigens in the periphery and migrate to lymphoid organs in order 
to initiate immunity (Steinman and Inaba, 1999). In aGvHD and cGvHD patients the absolute 
numbers of mDCs in blood were found to be decreased (Akhtari et al., 2010; Lau et al., 
2007). Increased numbers of Treg cells (CD4+ CD25+ FoxP3+) which help to maintain 
immune tolerance and to promote immune reconstitution after HSCT, were found to prevent 
aGvHD (Magenau et al., 2010; Rezvani et al., 2006; Wolf et al., 2007).  
HGF is a multifunctional cytokine produced by mesenchymal cells and mainly targeting 
epithelial cells. In the serum of aGvHD patients increased HGF concentrations correlated 
with the severity of aGvHD (Okamoto et al., 2001). However, HGF also has anti-apoptotic 
properties resulting in enhanced liver repair and regeneration (Luft et al., 2007). For instance, 
HGF administration in an aGvHD mouse model resulted in the prevention of aGvHD 
(Kuroiwa et al., 2001). Therefore it may not only indicate the degree of organ damage but 
also estimate the response to narrow down further damage from GvHD. 
Several studies confirmed that sIL-2R levels are elevated in aGvHD and cGvHD patients 
(Foley et al., 1998; Miyamoto et al., 1996; Visentainer et al., 2003). Presumably a set of 
several biomarkers will be more informative for the prediction of GvHD than one single 
biomarker. In 2011, August et al. monitored the mean serum level of sIL-2R and TNF-R1 
during the first month after allogeneic HSCT. They found that that sIL-2R and TNF-R1 levels 
increased during the first two weeks after transplantation in patients with aGvHD. Based on 
these findings they postulated that aGvHD occurrence is predictable using sIL-2R and TNF-
R1 levels together with CD8 as biomarkers (August et al., 2011). 
 
2.5. Objectives 
This PhD project deals with cellular mechanisms and the optimization of the ECP protocol 
currently used in the clinic and the identification of related biomarkers. ECP therapy is a 
second-line treatment frequently performed in patients suffering from aGvHD and cGvHD. 
However, the apheresis procedure is physically exhausting especially for patients with 
severe aGvHD. In addition several patients are refractory to this treatment. In this case, a 
modification of the ECP procedure would be beneficial. This could be achieved, for instance, 
by replacing the patient’s own leukocytes by those from a third party donor, thereby saving 




Based on this background, we wanted to modify and optimize ECP therapy using well known 
mouse models of aGvHD and cGvHD. One major goal was to improve the course of disease 
by changing the original ECP setup using cells derived from healthy mice. For this purpose, 
MHC matched and mismatched leukocytes derived from different donor mouse strains 
(C57BL/6, C3H, BALB/c) as well as cells activated in vitro were used as grafts and their 
efficacy in ameliorating the clinical disease course was tested. Additionally, the cellular 
mechanism was investigated by studying the frequency of different leukocyte populations.  
In parallel, we not only wanted to improve ECP therapy but also try to predict whether 
patients would suffer from GvHD or respond to ECP therapy. Biomarkers could be a helpful 
tool to achieve both.  
Hence, in the course of this study the ground for identification of putative GvHD and ECP 
biomarker should be layed. As a first step blood and serum samples of allogeneic 
transplanted patients, steroid-refractory patients receiving ECP therapy, and healthy blood 
donors were collected.  As a second step, different cell subpopulations and cytokine levels 
should then be compared to determine reference values of healthy blood donors. During the 
last step we aimed to compare levels of potential biomarkers between healthy donors, HSCT 
patients and ECP patients.  
By combining mouse models and human samples we thought to obtain new insight allowing 
to make ECP therapy more tolerable for the patients and to predict the occurrence of GvHD 
and the responsiveness to ECP therapy. Taken together, this should contribute to a safer 
future application of HSCT for patients suffering from hematological malignancies. 
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3. Material and methods 
3.1. Material 
3.1.1. Technical equipment  
Tab. 1: Technical equipment 
Equipment Type Manufacturer 
Accu Jet pipetus Hirschmann, Eberstadt 
Autoclave FVA3 Fedegari, Munich 
Centrifuges Rotanta 46 RS Hettich, Kirchlengern 
Mikro 22R Hettich, Kirchlengern 
Universal 32R Hettich, Kirchlengern 
ProFuge TM 10K Stratagene California, La 
Jolla, USA 




Neubauer improved  
cell chamber  
Sarstedt, Nümbrecht 
ELISA spectrophotometer Magellan Sunrise Remote TECAN, Männedorf, Schweiz 
Flow Cytometer  BD FACS CANTO II  BD Bioscience, San Jose, 
USA 
Forceps variant types Fine Science Tools, 
Heidelberg 
Freezer -20°C, Comfort Liebherr, Kirchdorf 
Gamma Irradiator Biobeam 8000 Gamma-Service Medical, 
Leipzig 
Incubator Hera cell Heraeus, Hanau 
Infrared lamp  Sollux 750 Original Hanau, Hanau 
Irradiation unit Xstrahl RS225 Gulmay Medical Limited, 
Surray, UK 
MACS cell separator MACS TM Separator Miltenyi Biotec GmbH, 
Bergisch Gladbach 
Microplate mixer MTS-2 IKA- Werke, Staufen  
Mouse restrainer   scientific shop UMG, 
Göttingen 
Multi- Axle Rotating mixer IDL TRM-50 IDL, Schmitten 
PH- Meter Lab-pH-Meter 765 Knick, Berlin 
Pipettes Research, Reference, 
Multipette Plus 
Eppendorf, Hamburg 
Perspex box  scientific shop UMG, 
Göttingen 
Pocket scale for mice TEE150-1 Kern& Sohn, Balingen  
Refrigerator 8°C, Premium Liebherr, Kirchdorf 
Scale BP 41OS Sartorius AG, Göttingen 
Scissors variant types Fine Science Tools, 
Heidelberg 
Sterile bench Mikroflow biological 
safety cabinet  
NUNC , Roskilde, Denmark 
Transmitted-light 
microscope 
Axiostar ZEISS, Göttingen 
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Ultralow freezer -80°C NuAire, Plymouth, USA 
UV radiation device  Vilber Lourmat, Eberhardzell 
Vortexer Vortex-Genie 2 Scientific industries, New 
York, USA 




Tab. 2: Chemicals 
Chemicals Manufacturer 
9-Methoxyfuro[3,2-g][1]benzopyran-7-one (8-MOP) UMG, pharmacy, Göttingen 
2-Propanol Merck, Darmstadt 
Alkopharm 80 BrüggemannAlcohol, Heilbronn 
Ampuwa Fresenius Kabi, Bad Homburg 
Annexin Binding Buffer BioLegend, San Diego, USA 
Aqua bidest B.Braun, Melsungen  
AutoMACS Running Buffer-  
MACS R Separation Buffer 
Miltenyi Biotec, Bergisch 
Gladbach 
Cell Proliferation Dye eFluor R 450 eBioscience, Inc., San Diego, 
USA 
Concanavalin A Sigma-Aldrich, St. Louis, USA 
Dimethyl Sulfoxide ≥99.8%  Sigma-Aldrich, St. Louis, USA 
Ficoll-Paque TM PLUS GE Healthcare, 
Buckinghamshire, UK 
Foxp3 / Transcription Factor Fixation/Permeabilization 
Concentrate and Diluent 
eBioscience, Inc., San Diego, 
USA 
Heparin-Natrium 5000 (iE/0,2ml) Ratiopharm, Ulm 
Ionomycin calcium salt Sigma-Aldrich, St. Louis, USA 
Monensin Solution (1,000X) BioLegend, San Diego, USA 
Neomycin trisulfate salt hydrate  Sigma-Aldrich, St. Louis, USA 
Novaminsulfon Lichtenstein Tropfen (500mg/ml) Zentiva, Prague, Czech 
Republic 
PBS without Ca2+ and Mg2+ Thermo Fisher Scientific, 
Waltham, USA 
Phorbol 12-Myristate 13-Actetate Sigma-Aldrich, St. Louis, USA 
Phosphate Buffered Saline without Ca and Mg Lonza Group, Basel, Schweiz 
RBC Lysis buffer (10X) Sigma-Aldrich, St. Louis, USA 
Recombinant Murine PDGF-AA PeproTech EC Ltd., London, 
UK 
Tri- Sodium citrate dihydrate  Merck, Darmstadt 
 
  




Tab. 3: Consumables 
Equipment Specification Manufacturer 
Cell culture flasks 25 cm2 T-25 Flask, Cyto One Starlab, Ahrensburg 
Cell culture flasks 75 cm2, Cellstar Greiner Bio-One, Kremsmünster, 
Österreich 
Cell culture plates 5 cm Sarstedt, Nümbrecht 
Cell culture plates 10 cm Nunc A/S, Roskilde, Danmark 
Cell strainer 70 µm Nylon, Falcon Thermo Fisher Scientific, Waltham, 
USA 
Cell strainer 40 µm Nylon, Falcon Thermo Fisher Scientific, Waltham, 
USA 




5 ml Eppendorf, Hamburg 
Culture multiwell 
plates 
6-well Greiner Bio-One, Kremsmünster, 
Österreich 
FACS tube  5 ml, FALCON round bottom 
tube 
Corning Science, Mexico 




 Brand, Wertheim 
Gloves Nitril  Rösner-Mautby Meditrade, 
Kiefersfelden 
Insulin syringe U-100 Insulin, 30G, 0,3 ml BD, Durham, USA 
MACS LS  
Separation Columns  
Miltenyi Biotec GmbH, Bergisch 
Gladbach 
Parafilm  Pechiney, Paris, Frankreich 
Pipette tip 10 µl, 100 µl,1000 µl Starlab, Ahrensburg 
Pipette tip 2.5 µl Biozym Scientific, Hessisch Oldendorf 
Polystyrene 
conical tube 
15 ml BD, Durham, USA 
Reaction tube  0.5ml, 1ml ,2 ml Sarstedt, Nümbrecht 
Serological pipet 2 ml, 5 ml, 25 ml Falcon, Durham, USA 
Serological pipet 10 ml Sarstedt, Nümbrecht 
S-Monovette Heparin, 4.7 ml Sarstedt, Nümbrecht 
S-Monovette Clotting Activator/Serum 2.7 
ml 
Sarstedt, Nümbrecht 
Surgical headwear  Mölnlycke Health Care, Göteburg, 
Sweden 
Surgical mask  Farstar medical GmbH, Barsbüttel  
Syringe  5ml BD, Durham, USA 
Syringe with 
needle 
1 ml, 26 GA 3/4 IN, 0.45x10 
mm 
BD, Durham, USA 
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3.1.4. Antibodies for cell separation  
Tab. 4: Antibodies for cell separation 
Antigen Isotype Manufacturer µg or µl 
/ 100 µl 
incubation 
[min]    [°C]  
CD90.2 Micro 
Beads 
Rat IgG2b Miltenyi Biotec GmbH, 
Bergisch Gladbach 
10 µl 15 4 
 
3.1.5. Antibodies for flow cytometry 
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3.1.5.1. Mouse antibodies  
Tab. 5: Mouse antibodies 
Antigen Fluorochrome Clone Isotype Manufacturer µg or µl  
/ 100 µl 
incubation 
[min]  [°C]  
Annexin V Pacific Blue - all mammalian 
species 
BioLegend, San Diego, USA 0.1 µg 10 RT 
Annexin V FITC - all mammalian 
species 
BioLegend, San Diego, USA 0.2 µg 10 RT 
CD117 
antibodies 
APC 3C1 Rat IgG2b Miltenyi Biotec GmbH, Bergisch 
Gladbach 
10 µl 10 4 
CD229.1 APC 30C7 Rat IgG2a  BD Biosciences, New Jersey, USA 0.5 µg 20 4 
CD25 PE PC61.5 Rat IgG1, lambda eBioscience, Inc., San Diego, USA 0.1 µg 10 4 
CD3 Pacific Blue 17A2 Rat IgG2b BioLegend, San Diego, USA 0.25 µg 15 4 
CD3 Epsilon Pacific Blue TM 145-2C11 Armenian Hamster 
IgG 
BioLegend, San Diego, USA 2.5 µg 15 RT 
CD3e  PE 145-2C11 Amenian Hamster IgG eBioscience, Inc., San Diego, USA 0.3 µg 10 RT 
CD4 FITC RM4-5 Rat IgG2a, k eBioscience, Inc., San Diego, USA 0.25 µg 10 RT 
CD45 PE 30-F11 Rat IgG2b, k BioLegend, San Diego, USA 0.1 µg 10 RT 
CD45 eFluor 30-F11 Rat IgG2b, k eBioscience, Inc., San Diego, USA 0.1 µg 20 4 
CD45 FITC 30-F11 Rat IgG2b, k eBioscience, Inc., San Diego, USA 0.25 µg 20 4 
CD45.1 APC A20 Mouse IgG2a, k BioLegend, San Diego, USA 0.1 µg 10 RT 
CD45R/B220 FITC RA3-6B2 Rat IgG2a, k BioLegend, San Diego, USA 0.5µg 20 4 
CD49b 
(pan-NK cells) 
APC DX5 Rat IgM, k BioLegend, San Diego, USA 0.25 µg 15 RT 
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CD8a APC 53-6.7 Rat IgG2a, k BioLegend, San Diego, USA 0.1 µg 10 RT 
FoxP3 APC FJK-16s Rat IgG2a, k eBioscience, Inc., San Diego, USA 0.5 µg 20 4 
gamma delta 
TCR 
APC GL3 Hamster IgG BioLegend, San Diego, USA 0.2 µg 10 RT 
H-2Db PE KH95 Mouse (BALB/c) 
IgG2b, k 
BioLegend, San Diego, USA 0.1 µg 20 4 
H-2Dd Alexa Fluor R 
647 
34-2-12 Mouse (C3H/HeJ) 
IgG2a, k 
BioLegend, San Diego, USA 0.15 µg 20 4 
H-2Dk PE 15-5-5 Mouse (C3H.SW) 
IgG2a, k 
BioLegend, San Diego, USA 0.2 µg 20 4 
H-2Kb Pacific Blue  AF6-88.5 Mouse (Balb/c) H-2Kb BioLegend, San Diego, USA 0.5 µg 20 4 
IFN gamma PE XMG1.2 Rat IgG1, k BioLegend, San Diego, USA 1 µg 15 RT 
IL-2 APC JES6-5H4 Rat IgG2b, k BioLegend, San Diego, USA 0.25 µg 15 RT 
Lineage Cell  
Detection 
Cocktail-Biotin 














IgG1, k ; IgG2b, k Miltenyi Biotec GmbH, Bergisch 
Gladbach 
10 µl 10 4 
MACS Control 
CD90.2 T Cell 
Cocktail 
PE, VioBLue 30-H12; 
30F11 
Rat IgG2b; Rat IgG2b Miltenyi Biotec GmbH, Bergisch 
Gladbach 

























TNF alpha APC MP6-xT22 Rat IgG1, k BioLegend, San Diego, USA 0.25 µg 15 RT 
Trustain fcXTM (CD16/32) 93 Rat IgG2a y BioLegend, San Diego, USA 1 µg 10 4 
Anti-Biotin 
antibodies 
FITC Bio3-18E7 Mouse IgG1 Miltenyi Biotec GmbH, Bergisch 
Gladbach 
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3.1.5.2. Human antibodies 
Tab. 6: Human antibodies 
Antigen Fluorochrome Clone Isotype Manufacturer µg or µl 
 / 100 µl 
incubation 
[min]     [°C]  
Annexin V  FITC - - BioLegend, San Diego, USA 1 µl 10 RT 
CD 45  PE 2D1 Mouse IgG1, k eBioscience, Inc., San Diego, USA 0.0125 µg 10 RT 
CD11c APC Bu15 Mouse IgG1, k BioLegend, San Diego, USA 0.25 µg 30 4 
CD19 FITC HIB19 Mouse IgG1, k eBioscience, Inc., San Diego, USA 0.125 µg 30 4 
CD21 APC HB5 Mouse IgG2a, k eBioscience, Inc., San Diego, USA 0.015 µg 30 4 
CD25  PE M-A251 Mouse IgG1, k BioLegend, San Diego, USA 0.5 µg 10 RT 
CD3 FITC HIT3a Mouse IgG2a, k BioLegend, San Diego, USA 1 µg 10 RT 
CD4 Pacific Blue  RPA-T4 Mouse IgG1, k BioLegend, San Diego, USA 2.5 µg 10 RT 
CD4 eFluor RPA-T4 Mouse IgG1, k eBioscience, Inc., San Diego, USA 0.05 µg 10 RT 
CD8a PE SK1 Mouse IgG1, k eBioscience, Inc., San Diego, USA 0.075 µg 10 RT 
FoxP3 Alexa 647 206D Mouse IgG1, k BioLegend, San Diego, USA 0.3 µg 20 RT 
HLA-DR  PerCP-Cy5.5 LN3 Mouse IgG2b, k eBioscience, Inc., San Diego, USA 0.0075 µg 30 4 
Human  
TruStain FcX  
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3.1.5.3. Isotype controls 
Tab. 7: Isotype controls 
Antigen Fluorochrome Clone Manufacturer 
Armenian 
Hamster IgG 
Pacific Blue HTK888 BioLegend, San Diego, 
USA 
ms IgG1 k APC P3.6.2.8.1 eBioscience, Inc., San 
Diego, USA 
ms IgG1 k eFluor 450 P3.6.2.8.1 eBioscience, Inc., San 
Diego, USA 
ms IgG1 k  PE MOPC-21 BioLegend, San Diego, 
USA 
ms IgG1 k  Alexa Fluor 647 MOPC-21 BioLegend, San Diego, 
USA 
ms IgG1 k  PerCP-Cy5.5 P3.6.2.8.1 eBioscience, Inc., San 
Diego, USA 
ms IgG2a k  eFluor 450 eBM2a eBioscience, Inc., San 
Diego, USA 
ms IgG2a k  APC eBM2a eBioscience, Inc., San 
Diego, USA 
ms IgG2b k  PerCP Cy5.5 eBMG2b eBioscience, Inc., San 
Diego, USA 
msIgG1  FITC MOPC-21 BD Bioscience, San Jose, 
USA 
msIgG1 k  eFluor 450 P3.6.2.8.1 eBioscience, Inc., San 
Diego, USA 
msIgG1 k  PE P3.6.2.8.1 eBioscience, Inc., San 
Diego, USA 
msIgG2a k  FITC MOPC-173 BioLegend, San Diego, 
USA 
rat IgG1, k APC RTK2071 BioLegend, San Diego, 
USA 
rat IgG1, k PE RTK2071 BioLegend, San Diego, 
USA 
rat IgG2a k APC R35-95 BD Bioscience, San Jose, 
USA 
rat IgG2a k PE eBR2a eBioscience, Inc., San 
Diego, USA 
rat IgG2b k  Pacific Blue RTK4530 BioLegend, San Diego, 
USA 
rat IgG2b, k APC RTK4530 BioLegend, San Diego, 
USA 
 
3.1.6. Commercial Kits 
Tab. 8: Commercial Kits 
Name Manufacturer 
BIOSOURCE sTNF-R1 EASIA kit BioSource Europe S.A., Nivelles, Belgium 
Cell Proliferation Dye eFluor R 450 eBioscience, Inc., San Diego, USA 
ELISA Kit Human HGF Invitrogen, Camarillo, USA 
ELISA Kit Human sIL-2R Instant ELISA eBioscience, Inc., San Diego, USA 
ELISA Kit sTNF-R (60kDa) Instant ELISA eBioscience, Inc., San Diego, USA 
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ELISA Mouse TGF beta 1 Platinum eBioscience, Inc., San Diego, USA 
HUMAN HGF Instant ELISA  eBioscience, Inc., San Diego, USA 
IL2R Human ELISA Kit Thermo Fisher Scientific, Waltham, USA 
Pan T Cell Isolation Kit II Miltenyi Biotec GmbH, Bergisch Gladbach 
 
3.1.7. Commercial media and supplements 
Tab. 9: Commercial media and supplements 
Name Manufacturer 
HI Fetal Calf serum (FCS) Thermo Fisher Scientific, Waltham, USA 
Penicillin/Streptomycin 
(Pen/Strep)(10000U/ml) 
Gibco by Thermo Fisher Scientific, Waltham, 
USA 
RPMI Medium 1640 (1x)+ GlutaMAX  Gibco by Thermo Fisher Scientific, Waltham, 
USA 
 
3.1.8. Buffers, media, solutions 
Tab. 10: Buffers, media, solutions 
Buffers/media/solutions Composition 
Drinking water for mice 100 ml Neomycine Stock Solution 
900 ml H2O 
2.8 ml Metapyrin 
Fixation/Permeabilization Buffer (1X) 1 part of Fixation/Permeabilisation 
Concentrate (4X) 
3 parts of Fixation/Permeabilisation 
Diluent 
Freezing medium 70% RPMI Medium 1640 (1x)+ 
GlutaMAX  
20% HI Fetale Calf Serum 
10% dimethylsulfoxide (DMSO) 
MACS Buffer AutoMACS Running Buffer 
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MLR cell culture medium  
(MLR Medium) 
500 ml RPMI Medium 1640 (1x)+ 
GlutaMAX 
5 ml Penicillin/Streptomycin 
(Pen/Strep)(10000U/ml) 
50 ml HI Fetal Calf serum 
Sodium acetate (NaCi) Buffer 1 part NaCi Stock solution 
1 part PBS without Ca2+ and Mg 2+ 
Sodium acetate (NaCi) Stock solution 73.5 g tri- Sodium acetate dihydrate 
1 l distilled H2O 
Neomycin Stock solution 250 mg Neomycin trisulfate salt 
hydrate  
in 1 l H20 
Permeabilization Buffer (1X) 1 part Permeabilisation Buffer (10X) 
9 parts distilled water  
Drinking water for mice 100 ml Neomycine Stock Solution 
900 ml H2O 
2.8 ml Metapyrin 
Fixation/Permeabilization Buffer (1X) 1 part of Fixation/Permeabilisation 
Concentrate (4X) 
3 parts of Fixation/Permeabilisation 
Diluent 
Freezing medium 70% RPMI Medium 1640 (1x)+ 
GlutaMAX  
20% HI Fetale Calf Serum 
10% DMSO 
MACS Buffer AutoMACS Running Buffer 
MLR cell culture medium 500 ml RPMI Medium 1640 (1x)+ 
GlutaMAX 
5 ml Penicillin/Streptomycin 
(Pen/Strep)(10000U/ml) 
50 ml HI Fetal Calf serum 
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Sodium citrate Buffer 
(NaCi Buffer) 
1 part NaCi Stock solution 
1 part PBS without Ca2+ and Mg 2+ 
Sodium citrate stock solution 73.5 g tri- Sodium acetate dihydrate 
1 l distilled H2O 
Neomycin stock solution 250 mg Neomycin trisulfate salt 
hydrate  
in 1 l H20 
Permeabilization Buffer (1X) 1 part Permeabilisation Buffer (10X) 
9 parts distilled water  
 
3.1.9. Mouse strains 
Tab. 11: Mouse strains 
Strain Company 
B10.D2n5nJ The Jackson Laboratory, Bar Harbor, USA 
B6.SJL_PtprcaPepcb/BoyJ AG Lühder, Genetical Neuroimmunology, UMG, Göttingen 
BALB/cAnNCrl Charles River Laboratories, Wilmington, USA 
C3H/HeN Rj JANVIER LABS, Le Genest-Saint-Isle, France 
C57BL/6JRj JANVIER LABS, Le Genest-Saint-Isle, France 
 
3.1.10. Software 
Tab. 12:  
Tab. 12: Software 
Software Manufacturer 
BD FACS Diva Software Version 
6.1.2 
BD Biosciences, New York, USA 
Graphpad Prism 6 GraphPad Software, Inc., La Jolla, USA 
Magellan Software  TECAN, Männedorf, Schweiz 
Microsoft Office 2007 & 2010 Microsoft Corporation, Redmond, USA 
 
3.2. Methods 
3.2.1. Cellular methods 
3.2.1.1. Flow cytometric analysis 
Human MNCs or murine cells in suspension were transferred into a fluorescence-activating 
cell sorting (FACS) tube and washed wit 2 ml magnetic-activating cell sorting (MACS) buffer 
for 10 min at 350 g. The supernatant was discarded and the cell pellet resuspended in MACS 
buffer. Afterwards Fc-receptors were blocked using 2 µl TruStain for human and CD16/32 for 
murine cells for 10 min at 4°C. Following Fc-receptor blockage, the cells were incubated with 
one or more monoclonal antibodies conjugated to fluorochromes in the dark. Optimization of 
Material and methods 
29 
 
incubation time and temperature was performed for each antibody and is listed in 3.1.5.1. , 
and 3.1.5.2.. Subsequently the cells were washed with 2 ml MACS buffer and analyzed with 
a flow cytometer (FACS Canto II). The usage of more than one antibody required a 
compensation setup to control spectral overlap. Data were analyzed with BD FACS DIVA 
software version 6.1.2.. 
 
3.2.1.1.1. Intracellular staining methods 
3.2.1.1.1.1. Cytokine assay 
This procedure was performed with mouse spleen or lymph node cell suspensions. Single 
cell suspensions were prepared (3.2.1.1.4.) and centrifuged at 300 g at RT for 7 min. 
Afterwards the supernatant was aspirated with a glass pasteur pipette. The cell pellet was 
resuspended in RPMI medium and added on multi-well culture plates or cell culture flasks. 
Prior to detection of intracellular cytokine expression by flow cytometry, the cells had to be 
stimulated. Therefore 40 ng/ml phorbol 12-myristate 13 acetate (PMA), 2 µM ionomycin 
calcium salt (IM) and 1 µl/ml of 1x monensin solution (MN) were added to the cells and 
incubated for 5 hrs at 37°C and 0.5% CO2. Following incubation, the cells were transferred 
into 50 ml centrifuge tubes and washed with MACS buffer twice by centrifugation at 300 g for 
7 min at room temperature (RT). Afterwards, the cells were counted using a Neubaur 
chamber (3.2.2.1.) and 1x106 cells diluted in 100 µl MACS buffer were transferred into 5 ml 
FACS tubes. The cells were fixed (3.2.1.1.1.2.) and incubated in the dark with IFN-γ-PE, IL-
2-APC or TNF-α-APC for 20 min at RT. Subsequently, the cells were washed twice with 2 ml 
permeabilization buffer and centrifuged at 300 g for 5 min at RT. Finally, the supernatant was 
decanted, the cells resuspended in 200 µl MACS buffer and analyzed using flow cytometry. 
 
3.2.1.1.1.2. Fixation of cells for intranuclear staining 
This procedure was performed using the forkhead box protein 3 (FoxP3) Fixation and 
Permeabilization Buffer Set from eBioscience. 1x106 cells were resuspended in 500 µl 
fixation buffer and incubated at 4°C for 10 min. In this step, live cells were fixed with 
formaldehyde to stabilize cellular structures. Afterwards, the cells were washed twice with 2 
ml permeabilization buffer and centrifuged at 350 g for 5 min at RT to generate pores in the 
membrane so that fluorochrome-conjugated monoclonal antibodies could enter the cell. The 
supernatant was discarded and the cells were resuspended in 100 µl permeabilization buffer. 
Subsequently, the optimized amount of fluorochrome-conjugated antibody was added and 
incubated in the dark (3.1.5.1. and 3.1.5.2.). Following incubation the cells were washed 
twice with permeabilization buffer and analyzed using flow cytometry. 




3.2.1.1.2. Staining of cell surface markers 
3.2.1.1.2.1. Chimerism analysis 
The analysis of chimerism is a tool to assess the origin of leukocytes after allogeneic stem 
cell transplantation. This analysis was conducted at least 6 weeks post BMT. Therefore 
transplanted C57BL/6->BALB/c mice were sacrificed with carbon dioxide (CO2) and cervical 
dislocation. Femur and tibia were isolated and placed into a petri dish containing icecold 
MACS buffer. After cleaning bones from skin, muscles and flesh both ends of the bones were 
cut off with sterile scissors. The BM was flushed out of the shaft with MACS buffer using a 1-
ml syringe and a 26 GA 3/8IN needle. The shaft was flushed until the bone appeared white 
and the cells were collected into a 50 ml tube. The cells were washed with 20 ml MACS 
buffer and centrifuged at 300 g for 10 min at 4°C. The supernatant was discarded and the 
cells counted with a Neubaur chamber (3.2.2.1.). 1x106 BM cells resuspended in 100 µl 
MACS buffer were incubated with 2 µl CD16/32 for 10 min at 4°C. Afterwards 0.5 µl of anti-
CD45 and 0.3 µl anti-H-2Dd monoclonal antibodies were added and the mixture was 
incubated for 20 min at 4 °C in the dark. The cells were then washed with 2 ml MACS buffer 
and centrifuged at RT at 350 x g for 5 min. The cell pellet was resuspended in 200 µl MACS 
buffer and analyzed using a FACS Canto II and FACS DIVA software. 
 
3.2.1.1.2.2. Detection of apoptotic cells 
To identify apoptotic cells by flow cytometry, 107 cells were transferred into a 5 ml FACS tube 
and washed twice with MACS buffer following centrifugation at 350 g for 5 min at RT. The 
supernatant was discarded and the cells were resuspended in 100 µl Annexin-V-binding 
buffer. Afterwards 2 µg Annexin-V-FITC was added and incubated for 10 min at RT in the 
dark. Following incubation, 400 µl Annexin-V-binding buffer was added and the cells were 
analyzed using a flow cytometer. 
 
3.2.1.1.3. Labeling cells with Cell Proliferation Dye eFluor® 670 
Murine splenocytes in single cell suspension (3.2.1.1.4.2.) were labeled with 10 µg/ml Cell 
Proliferation Dye eFluor® 670 according to the manufacturer’s instructions. In brief, the cells 
were resuspended at 2-fold the desired final concentration with MACS buffer in a 50 ml 
centrifuge tube and mixed 1:1 with 10 µM Cell Proliferation Dye solution diluted in MACS 
buffer. This suspension was incubated for 10 min at 37 °C in the dark. Labeling was stopped 
by adding five volumes of cold RPMI medium without P/S and incubation on ice for 5 min. 
Subsequently, the cells were washed three times with RPMI medium and centrifuged at 300 
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g for 7 min at RT. Following these washing steps, 107 cells were plated on 6-well culture 
plates with 2 ml RPMI medium per well. 
 
3.2.1.1.4. Preparation of lymphocyte single cell suspension 
3.2.1.1.4.1. Isolation of human lymphocytes 
Venous blood was drawn into two 4.7 ml S-Monovettes containing Lithium/Heparin-gel and 
mixed thoroughly. MNCs were separated via Ficoll Paque density centrifugation. Blood from 
both S-Monovettes was transferred into a 50 ml centrifugation tube and mixed with an equal 
volume of sodium acetate buffer (NaAc buffer). The diluted blood was carefully layered into 
another 50 ml centrifugation tube containing 20 ml Ficoll-Paque PLUS and centrifuged at 800 
g for 30 min at RT. The upper layer of plasma was removed using a glass pasteur pipette 
without disturbing the lymphocyte layer at the interface. The lymphocyte layer was then 
transferred into a 50 ml centrifugation tube, mixed with at least three volumes of NaAc buffer 
and centrifuged at 100 g for 10 min at RT. Subsequently, the cells were frozen as described 
in chapter 3.2.1.1.5.. 
 
3.2.1.1.4.2. Isolation of murine lymphocytes 
Mice were sacrificed and the lymph nodes (superficial cervicals, axillary, brachial, 
mesenteric, inguinal) and/-or spleen were removed and transferred to a cell culture plate 
containing ice-cold MACS buffer. Under sterile conditions (3.2.2.) single cell suspensions 
were prepared by pushing lymph nodes through cell strainers with a 40 µm nylon mesh using 
the plunger of a 5 ml syringe. The nylon mesh was washed several times with MACS buffer. 
Alternatively splenocytes were flushed out of the spleen with MACS buffer by using a 1 ml 
syringe armed with a needle. The spleen was washed about 30 times until the organ 
appeared white and the cells were transferred into a 50 ml centrifugation tube. Subsequently, 
the cell number was determined by counting using a Neubaur chamber (3.2.2.1.). 
 
3.2.1.1.5. Freezing of human lymphocytes 
After having centrifuged the lymphocytes, the supernatant was aspirated with a glass pasteur 
pipette and the pellet mixed with 700 µl RPMI medium and 200 µl HI fetal calf serum and 
placed on ice for 10 min. Following incubation, the cell suspension was transferred into 
freezing tubes. 100 µl DMSO was added drop-wise and carefully mixed. Afterwards, the 
tubes were placed in a cold isopropanol-filled cooling container at -80 °C. 
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3.2.1.1.6. Thawing human lymphocytes 
Frozen human lymphocytes were thawed quickly to minimize cell damage. Therefore 
freezing tubes containing the samples were transferred to a 37 °C water bath and 1 ml 
prewarmed RPMI medium was added drop-wise to the freezing tube. Afterwards, the cell 
suspension was transferred to a 50 ml centrifugation tube that was filled with prewarmed 9 
ml RPMI medium and centrifuged at RT for 7 min at 350 g. The supernatant was decanted 
and the cell pellet resuspended in 1 ml MACS buffer for further flow cytometric analyses 
(3.2.1.1.). 
 
3.2.1.1.7. Red blood cell lysis 
After preparation of splenic single cell suspensions in MACS buffer (3.2.1.1.4.2.), the cells 
were centrifuged at RT at 400 g for 5 min. To remove erythrocytes, the cell pellet was 
resuspended in 1 ml Red Blood Cell Lysis Buffer (1 ml per spleen) and mixed on a roller 
mixer for 1 min. The remaining white blood cells were washed with 20 ml MACS buffer and 
centrifuged at RT at 400 g for 7 min. The cells were resuspended in 1 ml MACS buffer and 
enumerated using a Neubaur chamber (3.2.2.1.).  
 
3.2.1.2. Enzyme-linked immunosorbent assay (ELISA) 
ELISA analysis of human or mouse serum (3.2.4.4.) served to quantify human HGF, sTNF-R, 
sIL-2R or murine transforming growth factor-β1 (TGF-β1). Instant ELISA kits were purchased 
from eBioscience and performed according to the manufacturer’s instructions. The principle 
of the ELISA assay exemplified for the human sIL-2R Instant ELISA kit. 
The samples were diluted 1:10 with distilled water and added to the wells of a microtiter plate 
pre-coated with anti-human sIL-2R antibody. During incubation at RT on a microplate shaker 
for 3 hrs human sIL-2R present in the sample bound to the absorbed antibody on the botton 
of the wells. A second horseradish peroxidase (HRP)-conjugated monoclonal anti-human 
sIL-2R antibody was added and incubated to bind to human sIL-2R captured by the first 
antibody. Subsequently, each well was washed 3 times with 400 µl wash buffer to remove 
unbound enzyme-conjugated anti-human sIL-2R. After the washing steps, 100 µl TMB 
substrate solution that was reactive with HRP was added to all wells and incubated for 10 
min at RT. The substrate reaction was stopped by adding 100 µl stop solution when the 
highest standard changed to a dark blue colour.  The absorbance in each well was 
determined using a spectrophotometer at 450 nm wave length.  
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3.2.2. Cell culture 
Primary cell culture work such as the preparation of murine BMT, ECP treatment or the 
establishment of mixed lymphocyte reaction (MLR) was conducted under a sterile bench and 
by using sterile reagents and consumables. If not otherwise specified, primary murine cells 
were cultured at 37°C and 5% CO2. Dependent on each purpose, the cells had to be cultured 
in flasks or multiwell plates. During each washing steps, the cells were transferred into sterile 
tubes and centrifuged outside of the sterile bench. Following centrifugation, the tubes were 
disinfected before returning them to the sterile bench. 
 
3.2.2.1. Determination of the cell number 
The number of cells was determined using a haemocytometer. To this end, 10 µl of the cell 
suspension was added to a Neubaur chamber. Two squares placed at the corner of the 
chamber were used for counting white blood cells. The number of cells was calculated using 
the following formula: average of counted cells per square x dilution factor x volume (ml) x 
104. 
 
3.2.2.2. Mixed Lymphocyte Reaction 
For conduction a MLR, the spleens of two donor mice (BALB/c, C57BL/6 or C3H) were 
dissected. Splenocytes of BALB/c origin served as stimulator cells whereas splenocytes of 
C57BL/6 or C3H origin served as responder cells. The splenocytes were placed into two 
separate cell culture plates filled with ice-cold MACS buffer. The cell suspensions were 
prepared under sterile conditions (3.2.1.1.4.2.) and transferred into sterile 50 ml 
centrifugation tubes. After red blood cell lysis (3.2.1.1.7), responder cells derived from 
C57BL/6 or C3H mice were resuspended in MLR medium (RPMI medium + 10-% FCS + 1-% 
P/S). The stimulator cells were mixed with 5 ml MACS buffer transferred into a 25 cm2 cell 
culture flask, and γ-irradiated with a dose of 30 Gy to abolish the capacity to proliferate. 
Afterwards, the stimulator cells were washed with 10 ml MACS buffer, centrifuged at 350 g 
for 10 min at RT and resuspended in 5 ml MLR medium. Both, the stimulator and the 
responder cells were counted using a Neubauer chamber (3.2.2.1.). MLRs were carried out 
in 6-well plates with 2.5x106 irradiated stimulator cells and 2.5x106 responder cells in a 
volume of 2 ml MLR medium. This co-culture was incubated at 37°C and 0.5 % CO2 for 4 
days. As a control for ECP therapy with MLR-derived cells, 5x106 irradiated stimulator cells 
were cultured alone in 2 ml MLR medium for 4 days at 37°C and 0.5 % CO2. 
 




Male and female BALB/cAnNCrl (BALB/c) mice were purchased from Charles River. Male 
C57BL/6J Rj and C3H/HeN Rj mice were obtained from JANVIER. Female B10.D2n5nJ mice 
were purchased from The Jackson Laboratories. Male C57BL/6.SJLPtprcaPepcb/BoyJ mice 
(CD45.1 congenic mice C57BL/6J) (Uhmann et al., 2011) were used as donor animals and 
were a kind gift of Dr. Fred Lühder (UMG Göttingen). The animals were housed in groups 
under pathogen-free conditions in individual ventilated cages (IVC) in the animal facility of 
the UMG in Göttingen. The mice were supplied with food and water ad libitum and housed in 
a standard 12 hour light/ dark cycle.   
 
3.2.3.1. Ethical statement 
All animal experiments were conducted according to Lower Saxony state regulations and 
approved by the responsible authority (Nds. Landesamt für Verbraucherschutz und 
Lebensmittelsicherheit). Starting one day prior to BMT, the drinking water of the recipient 
mice was supplemented with the analgetics metamizole to reduce pain, and with neomycin to 
avoid bacterial infection. The drinking water was changed every other day.  
 
3.2.3.2. Irradiation of recipient mice 
One day before BMT male BALB/c recipient mice were irradiated. The dose rate of 1 Gy/min 
was delivered by using a RS 225 X-Ray Research System operated at 200 kV, 15 mA and 
with 0.5-mm Cu filtration. To this end, the mice were placed in a customized Perspex box 
and received a total dose of 9.5 Gy. 
 
3.2.3.3. Intravenous injection into the tail vein 
Initially, the mice were warmed up carefully with an infrared lamp to stimulate dilatation of the 
tail veins. Subsequently, they were placed in a mouse restrainer to limit the movements. The 
tail was straightened with one hand while with the other one the material was injected into 
one of the lateral tail veins with an insulin syringe. Right afterwards the mouse was released 
and the restraining device was disinfected thoroughly to avoid infections. 
 
3.2.3.4. Induction of GvHD 
3.2.3.4.1. T cell purification 
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After sacrificing the mice, lymph nodes and spleen were dissected. The T cells were isolated 
under sterile conditions using MACS technology. o this end Pan T Cell Isolation Kit II was 
used according to manufacturer`s instructions.  Each cell suspension was centrifuged at 300 
g for 10 min at 4°C. The supernatant was removed completely and the cells were 
resuspended in 13 µl MACS buffer per 107 cells. The cells were then incubated with 3 µl Pan 
T Cell Isolation Kit II Antibody per 107 cells for 10 min at 4°C. Subsequently, 6.5 µl anti-Biotin 
Beads and 10 µl MACS buffer per 107 cells were added and incubated for 15 min at 4°C. 
Following incubation, the cells were washed with 4 ml MACS buffer and centrifuged at 300 g 
for 10 min at 4°C. The supernatant was discarded and cells were resuspended in 3 ml MACS 
buffer. Cell suspension was then pushed through a 40 µm nylon mesh and separated using a 
MACS Separator magnetically attached to MACS MultiStand. Purification of T cells was 
controlled by flow cytometry (3.2.1.1.) using a CD90.2 antibody. T cell purity was usually 
>95%.   
 
3.2.3.4.2. Preparation of bone marrow single cell suspensions 
The mice were sacrificed with CO2 followed by cervical dislocation. Tibia and femur were 
prepared, gently cleaned of skin and muscles and placed into ice cold MACS buffer in a petri 
dish. The following work was performed under sterile conditions under a bench (3.2.2.). Both 
ends of the tibia and femur were trimmed with sterile scissors. BM cells were flushed out of 
the shaft with MACS buffer using a 1-ml syringe armed with a 26GA 3/8IN needle. The shaft 
was flushed until the bones appeared white and the cells were collected in a 50 ml 
centrifugation tube. The BM cells were washed by filling up the tube with MACS buffer and 
centrifuged at 300 g for 10 minutes at 4°C. The supernatant was aspirated completely with a 
glass pasteur pipette and the cells were gently disaggregated by pipetting them up and down 
several times. Afterwards the cell suspension was passed through a 40 µm nylon mesh and 
the cell number was determined as described above (3.2.2.1.). 
 
3.2.3.4.3. T cell depletion of bone marrow cells 
After having prepared the single cell suspension of bone marrow cells, the T cells were 
depleted using MACS CD90.2 MicroBeads according to the manufacturer`s instructions. In 
brief, bone marrow cells were centrifuged at 300 g for 10 min at 4°C and the supernatant 
discarded. The cells were resuspended in 25 µl MACS buffer per 107 cells and incubated 
with 2.8 µl CD90.2 MicroBeads per 107 cells for 15 min at 4°C. The cells were passed 
through a 40 µm nylon mesh and separated using MACS Separator attached to MACS 
MultiStand. The T cell-depleted bone marrow cells were stained with 10 µl Lineage Cocktail, 
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10 µl anti-Biotin Beads, 10 µl anti-CD117 and 10 µl anti-CD90.2 cocktail and analyzed with 
flow cytometry. The preparation generally contained <1% T cells.  
 
3.2.3.4.4. Induction of acute GvHD 
One day after irradiation (3.2.3.2.), BMT was performed to induce aGvHD in mice (modified 
after Tischner et al., 2011). Male BALB/c mice between 10-12 weeks of age were used as 
recipients, whereas male 10 to 12 weeks old C57BL/6J Rj mice served as bone marrow and 
T cell donors. The donor mice were sacrificed with CO2 and cervical dislocation, spleen, 
lymph nodes, femur and tibia were dissected and single cell suspensions were prepared 
(3.2.1.1.4.2.). Next, T cell depletion of BM (3.2.3.4.3.) and T cell purification from spleen and 
lymph nodes were performed using MACS technique (3.2.3.4.1.). Afterwards the recipient 
mice were intravenously injected (3.2.3.3.) with 150 µl MACS buffer containing 107 T cell-
depleted bone marrow cells, 106 T cells from spleen and 106 T cells from lymph nodes. 
 
3.2.3.4.5. Induction of chronic GvHD 
Eleven weeks old female BALB/c mice were used as recipients whereas female B10.D2n5nJ 
served as donors for bone marrow and spleen. One day before bone marrow transplantation 
the recipient mice were irradiated with 9.5 Gy (3.2.3.2.). One day later, BMT was performed. 
To this end, the donor mice were sacrificed with CO2 and cervical dislocation and the spleen 
and bone marrow were dissected. Single cell suspensions were prepared (3.2.1.1.4.2.) and 
the T cells contained in bone marrow were depleted using MACS technology (3.2.3.4.3.) Red 
blood cell lysis was additionally performed with spleen cells (3.2.1.1.7.). Afterwards, the 
recipient mice were intravenously injected (3.2.3.3.) with 200 µl MACS buffer containing 107 
T cell-depleted bone marrow cells and 108 T cells from spleen. 
 
3.2.3.5. Analysis of GvHD pathology 
Starting one day after bone marrow transplantation, the recipient mice were weighed and 
monitored daily for clinical GvHD symptoms. The mice were assigned a score between 0 and 
2 for each of the following five criteria: posture, activity level, fur and diarrhea. The posture 
was evaluated based on a hunched appearance. A score of 0 indicated normal body posture, 
1 indicated a slightly hunched posture, 1.5 indicated a moderately hunched posture and 2 
indicated a strongly hunched posture. The activity level was evaluated based on the intensity 
with which the mouse moved in the cage. A score of 0 indicated a very active and normally 
moving behavior, 1 indicated a slightly reduced activity level, 1.5 indicated a mouse with 
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strongly reduced activity level, and 2 indicated a mouse that did not move at all or only 
moved after stimulation. Diarrhoea was evaluated after visual inspection of the anus of the 
mice. A mouse with a score of 0 indicated no diarrhea, 1 indicated little diarrhea or signs of 
inflammation, 1.5 indicated moderate diarrhea, and 2 indicated severe or sanguineous 
diarrhoea. The appearance of the fur was scored based on the level of hirsuteness. A score 
of 0 indicated normal fur, 1 indicated slightly fuzzy fur or scaly skin, 1.5 indicated severe 
fuzzy fur and 2 indicated severe fuzzy fur and regional fur loss. Each criterium was assigned 
a value between 0 (no symptoms) to 2 (severe symptoms) as outlined above. Hereby a 
maximum score of 8 could be reached. Due to ethical reasons mice were sacrificed when 
reaching a score of 6 of greater. Mice were also sacrificed when losing more than 25 % 
weight within 24 hours. To this end, the body weight of the mice was converted into percent 
of baseline body weight (referred to the day of BMT) to calculate the percentage of body 
weight loss during the study period. 
 
3.2.3.6. ECP therapy with cells of the donor mice 
The donor mice were sacrificed with CO2 and cervical dislocation. The spleens were 
collected into a petri dish filled with ice-cold MACS buffer. The splenocytes were flushed out 
with a 1-ml syringe armed with a 26 GA 3/8 IN needle under sterile conditions (3.2.2.) until 
the spleen appeared transparent. The cell suspension was collected into a 50 ml tube and 
centrifuged at RT at 300 g for 10 min. The supernatant was removed, the cell pellet 
resuspended in 1 ml Red Blood Cell Lysis Buffer and incubated on a roller mixer for 1 min 
(3.2.1.1.7.). Subsequently, 20 ml MACS buffer was added immediately to the cell suspension 
and centrifuged at RT at 350 g for 10 min. After discarding the supernatant the cell pellet was 
resuspended in 5 ml MACS buffer and transferred into a 15 ml tube wrapped in aluminium 
foil. The single cell suspension was incubated with 50 µl (0.2 µg/ml) of photoactive 8-MOP for 
30 min on a multi-axle rotating mixer at RT. Afterwards the suspension was transferred into a 
25 cm2 cell culture flask and exposed to 2 J/cm2 UV light in a UV-A irradiation device. The 
cell suspension was transferred into a 50 ml centrifugation tube and washed with 10 ml 
MACS buffer before determining the cell number (3.2.2.1.) and intravenous injection 
(3.2.3.3.) into the tail vein of C57BL/6->Balb/c transplanted mice. ECP therapy was 
performed four times in weekly intervals. The recipient mice received either 1 or 5x106 ECP 
cells diluted in 150 µl MACS buffer. Control animals were injected with 150 µl MACS buffer 
only. 
 
3.2.3.7. ECP therapy with cells isolated from MLR cultures 
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Cells from MLR cultures (3.2.2.2.) were transferred into a sterile 50 ml centrifugation tube 
filled with 10 ml MACS buffer and centrifuged at 350 g for 7 min at RT. Afterwards, the cell 
pellet was resuspended in 5 ml MACS buffer and transferred into a 15 ml centrifugation tube 
wrapped in aluminium foil. 50 µl (0.2 µg/ml) of photoactive 8-MOP were added to the cells 
and incubated for 30 min on a multi-axle rotating mixer at RT. The cells were then transferred 
into a 25 cm2 cell culture flask and exposed to 2 J/cm2 UV light in a UV-A irradiation device. 
The cell suspension was washed with 10 ml MACS buffer, transferred into a 50 ml 
centrifugation tube and centrifuged at 350 g for 10 min at RT. The cell pellet was 
resuspended in 5 ml MACS buffer and the cell number determined using a Neubauer 
chamber (3.2.2.1.). C57BL/6->BALB/c transplanted mice were intravenously injected 
(3.2.3.3.) with 106 ECP-treated MLR cells into the tail vein. ECP therapy with ECP-treated 
MLR cells was performed four times in weekly intervals. One cohort of C57BL/6->BALB/c 
transplanted mice received 106 ECP-treated MLR cells diluted in 150 µl MACS buffer 
whereas the control animals were injected with 106 ECP-treated irradiated stimulator cells 
(3.2.2.2.) diluted in 150 µl MACS buffer. 
 
3.2.3.8. Disinfection of the workplace and dissection set 
Before preparation of donor animals, the workplace was wiped with Alkopharm 80 and the 
scissors and forceps were disinfected in Alkopharm 80 for at least 20 min to work as sterile 
as possible. 
 
3.2.3.9. Murine serum collection 
Mice were sacrificed with CO2 inhalation and cervical dislocation and the thorax was opened 
using sterile forceps and scissors. The heart was punctured, the blood was transferred into a 
2 ml reaction contained and incubated for 10 min at RT. Afterwards, the blood was 
centrifuged for 10 min at RT at 350 g. The serum was transferred into a 1.5 ml freezing tube 
and stored at -20°C. 
 
3.2.4. Human blood sampling 
3.2.4.1. Patients and healthy blood donors 
Blood samples were taken from 25 healthy blood donors at two different dates with a 
minimum of three months between both donations, 30 patients with a haematologic 
malignancy before and after HSCT, and 12 GvHD patients before their first ECP therapy as 
well as three and six months afterwards. One healthy blood donor did not provide blood for 
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the second time point. Due to disease severity, blood could not be obtained from some 
GvHD patients three and six months after first ECP therapy. Blood samples of healthy blood 
donors served as control group. Serum samples were used for ELISA whereas heparin 
anticoagulated blood was used for further flow cytometric analysis (3.2.1.1.).  
 
3.2.4.2. Ethical statement for human blood samples 
Before conducting this study the use of whole blood and medical records was approved by 
the ethics committee of the UMG Göttingen. Informed consent was obtained from all study 
participants in written form after having been informed by a physician. Patients could 
withdraw their agreement any time during the study.  
 
3.2.4.3. Venous blood collection 
Venous blood was collected from patients and healthy blood donors. Blood was drawn into 
S-Monovettes containing either clotting activators for serum or Lithium/Heparin-Gel for 
heparin blood collection.  
 
3.2.4.4. Serum isolation of venous blood 
To obtain serum, the blood was drawn into S-Monovettes and stored for 30-60 min at RT in 
an upright position to allow clotting. The clot was removed by centrifugation at 350 g for 10 
min at RT. The resulting supernatant, was stored in 150 µl aliquots at -20 °C in 0.5 ml 
reaction tubes. 
 
3.2.5. Statistical analysis 
All calculations were performed with GraphPad Prism software. Survival rates were 
compared by Kaplan-Meier plots and the log-rank test was used to calculate the 
corresponding p-values. Flow cytometric data from different groups were compared using the 
non-parametric Mann-Whitney U test. Unless otherwise specified, data are depicted as bars 
showing the mean ±SEM. p-values <0.05 were considered as statistically significant. The 







4.1. Impact of ECP therapy on mouse models of aGvHD and cGvHD 
This study was conducted to investigate the therapeutic impact of PUVA-treated leukocytes 
derived from healthy donor mice (in the following designated “ECP therapy”) on the course 
and severity of acute and chronic GvHD. 
For induction of aGvHD, a well-defined allogeneic BMT mouse model was used (Tischner et 
al., 2011). This aGvHD mouse model is based on MHC class I and II as well as miHAs 
mismatches and is mediated by both CD4+ and CD8+ donor T cells (Schroeder and DiPersio, 
2011b). 
Additionally, a cGvHD mouse model was employed to study the impact of ECP therapy. For 
cGvHD induction, BALB/c recipient mice were transplanted with miHA-mismatched T and BM 
cells from wild-type B10.D2n5nJ (B10D2) donors. This mouse model is mediated by CD4+ T 
cells (Schroeder and DiPersio, 2011b). 
In both mouse models, the transplanted mice received the ECP therapy four times in weekly 
intervals starting at day two or three post BMT (Fig.3).  
 
 
Fig. 3: Scheme of GvHD induction and ECP thera py in the mouse m odel  
Fig. 3: Scheme of GvHD induction and ECP therapy in the mouse model.  
 
4.1.1. Impact of ECP therapy with cells from healthy mice on mouse models of GvHD 
4.1.1.1. ECP therapy with C57BL/6 splenocytes in a mouse model of aGvHD 
An experimental system of ECP therapy with splenocytes derived from healthy donor mice 
was established to examine whether this setup could ameliorate the severity and course of 
aGvHD. To this end, a total MHC-mismatch mouse model of aGvHD was used. Following 
aGvHD induction, one cohort of C57BL/6->BALB/c transplanted mice received 1x106 PUVA-
treated splenocytes whereas another cohort of recipient mice was injected with 5x106 PUVA-
treated splenocytes from wildtype C57BL/6 mice. As controls, C57BL/6->BALB/c mice were 




whole course of the experiment, the clinical score, survival rate and weight loss was 
monitored (Fig. 4) to assess the efficacy of the different treatment protocols. 
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Fig. 4: C57 BL/6 -> BALB/c transpla nted mice inje cted w ith PUVA-treate d C5 7BL/6 spl enocytes a s a mode l of ECP t herapy of aGvHD  
Fig. 4: C57BL/6->BALB/c transplanted mice injected with PUVA-treated C57BL/6 splenocytes 
as a model of ECP therapy of aGvHD. Irradiated BALB/c mice received allogeneic BMT followed by 
four weekly intravenous injections of PBS (black line, n= 19), 1x10
6 
(green line, n= 21) or 5x10
6
 (red 
line, n= 19) C57BL/6 splenocytes treated with 8-MOP and UV-A light. The therapeutic impact was 
analyzed by comparing the survival rates (A), clinical GvHD scores (B) and the weight loss (C).The 
Kaplan Meier plot shows survival rates and was analyzed using the log-rank test whereas the clinical 
scores and weight changes were analyzed with the Mann Whitney U test. Data are shown as means 
and are representative of three independent experiments. 
 
Fig. 4 shows that the survival rate (A) and clinical GvHD score (B) of mice injected with 1x106 
or 5x106 PUVA-treated splenocytes derived from C57BL/6 were not improved as compared 
to control mice. As depicted in Fig. 4C, there was also no reduction of weight loss in ECP-
treated mice compared to control mice (Budde et al., 2014). Furthermore, analysis of 




cells, CD4+ T cells or CD4+ CD25+ FoxP3+ Treg cells between PUVA-treated and control 
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Fig. 5: FACS analys is of splenocyte s from C57 BL/6 BA LB/c tra nspl ante d mice after ECP t herapy w ith splenocyte s of C57 BL/6 origin  
Fig. 5: FACS analysis of splenocytes from C57BL/6BALB/c transplanted mice after ECP 
therapy with splenocytes of C57BL/6 origin. C57BL/6->BALB/c mice received ECP therapy four 





treated splenocytes from C57BL/6 mice of PBS as control. The spleen of mice was analyzed when the 











 Treg cells (C) amongst all splenocytes are depicted. 
FACS analysis was conducted for 17 mice treated with 1x10
6
 PUVA-treated splenocytes, 17 mice 
treated with 5x10
6






4.1.1.2. ECP therapy with C57BL/6 splenocytes in a mouse model of cGvHD 
Up to this point, we had not observed any therapeutic effect of ECP therapy on the clinical 
GvHD score, weight or survival rate in C57BL/6->BALB/c transplanted mice when using 
PUVA-treated splenocytes from the BMT donor strain (C57BL/6). Therefore we repeated the 
experiment in a miHA-mismatch mouse model of cGvHD to examine whether PUVA-treated 
splenocytes derived from BMT donor strain would have an impact on the course and severity 
of cGvHD. As mentioned above, B10.D2 mice were used as donors for BMT to induce 
cGvHD. B10.D2->BALB/c mice were intravenously injected with 1x106 PUVA-treated B10.D2 
splenocytes four times in weekly intervals starting from day three post BMT. Mice injected 
with PBS served as controls. Subsequently, the survival rate (A), the clinical GvHD score (B) 
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Fig. 6: ECP therapy ameli orates disea se sympt oms in mice suffering from chronic GvH D  
Fig. 6: ECP therapy ameliorates disease symptoms in mice suffering from chronic GvHD. 
cGvHD was induced in irradiated BALB/c mice by transplanting T cell depleted BM cells and T cells 
from B10D2 mice. B10D2->BALB/c mice were intravenously injected four times in weekly intervals 
with 1x10
6




Meier plot shows the survival rate (A) and was analyzed using the log-rank test. The graphs also 
depict the impact of ECP therapy on the clinical score (B) and the weight loss (C), which were 
analyzed using the Mann Whitney U test. The data represent mean values. 
 
Fig. 6A shows that all B10D2->BALB/c mice injected with 1x106 PUVA-treated splenocytes of 
B10D2 origin survived whereas only 75% of the control mice survived 56 days post BMT. 
Furthermore, ECP-treated mice had a significantly lower clinical GvHD score than control 
animals (Fig. 6B, p<0.001). In contrast, ECP-treated mice lost significantly more weight than 
controls (Fig. 6C, p<0.001). Flow cytometric analysis of splenocytes from ECP-treated 
B10D2->BALB/c mice did not reveal differences in the percentages of CD4+ T cells or CD4+ 
CD25+ FoxP3+ Treg cells between mice injected with 1x106 B10D2 PUVA-treated 
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Fig. 7: FACS analys is of splenocyte s after ECP ther apy using cells of B10D 2 origin i n a mouse model of cGvHD  
Fig. 7: FACS analysis of splenocytes after ECP therapy using cells of B10D2 origin in a mouse 
model of cGvHD. B10D2 -> BALB/c transplanted mice were intravenously injected with PUVA-treated
 
splenocytes from B10D2 mice or PBS. ECP therapy was performed four times in weekly intervals 
starting from day 3 after BMT. The spleen was analyzed when mice reached a clinical GvHD score of 
≥6 or at day 56 post BMT. The percentages of CD4
+ 






 Treg cells 
amongst all splenocytes are shown. FACS analysis is based on 10 mice injected with 1x10
6
 PUVA-
treated splenocytes, and 7 control mice. The box-and-whisker plots represent the median ±25 to 75th 
percentile and min/max values. The data were analyzed with the Mann Whitney U test. 
 
4.1.1.3. ECP therapy with splenocytes of BALB/c origin 
Up to this point, ECP therapy with PUVA-treated splenocytes obtained from the BMT donor 




weight loss. Hence, I next investigated the therapeutic impact of ECP therapy on aGvHD 
employing splenocytes from healthy mice of the recipient mouse strain (BALB/c). To this end, 
C57BL/6->BALB/c mice were injected four times in weekly intervals with PUVA-treated 
BALB/c leukocytes starting at day three post BMT. The mice were weighed and GvHD 
clinical score was assessed daily for 56 days after BMT.  
As shown in Fig. 8A there was no difference in terms of survival rate between C57BL/6-
>BALB/c mice injected with PBS and those mice injected with 1x106 or 5x106 PUVA-treated 
BALB/c splenocytes. Furthermore, injection of 1x106 or 5x106 PUVA-treated BALB/c 
splenocytes even worsened the clinical GvHD score (Fig. 8B) as compared to controls (p< 
0.001/ p< 0.045), and significantly increased the weight loss (Fig. 8C) when compared to 
PBS-injected mice (p< 0.001).  
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Fig. 8: ECP therapy using PUVA -treated BALB/c sple nocytes aggravates a GvHD i n mice  
Fig. 8: ECP therapy using PUVA-treated BALB/c splenocytes aggravates aGvHD in mice. 
C57BL/6->BALB/c transplanted mice were injected four times in weekly intervals with either 1x10
6 
(green line, n= 14) or 5x10
6
 (red line, n= 14) PUVA-treated BALB/c splenocytes. Control mice (black 
line, n= 12) were transplanted simultaneously and infused PBS only at all therapeutic time points. The 
survival rate (A) is shown as Kaplan-Meier plot and was analyzed using the log-rank test. The 




and analyzed by use of the Mann Whitney U test. Data are shown as means and are representative of 
two independent experiments.  
 
To obtain more insights into the cellular processes taking place during treatment of aGvHD, 
splenocytes were isolated from C57BL/6->BALB/c mice after ECP therapy and analyzed by 
flow cytometry. More specifically the percentages of CD3+ T cells, CD3+ γδ T cells and CD4+ 
CD25+ FoxP3+ Treg cells amongst all splenocytes were assessed (Fig. 9). There were no 
differences found in percentages of CD3+ T cells and CD4+ CD25+ FoxP3+ Treg cells, 
whereas the percentages of CD3+ γδ T cells are decreased in control animals that survived 
the experiment compared to those mice which were treated with 1x106 (p=0.006) or 5x106 
(p=0.01) splenocytes of BALB/c origin and died during the experiment. Furthermore, those 
mice that survived and were treated with 5x106 BALB/c splenocytes showed decreased 
percentages of CD3+ γδ T cells compared to those which were treated with 1x106 
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Fig. 9: Flow cyt ometric analysis of sple nocytes isolated from C57 BL/6->BA LB/c mice after ECP t herapy w ith PUVA-treate d BALB/c spl enocytes  
Fig. 9: Flow cytometric analysis of splenocytes isolated from C57BL/6->BALB/c mice after ECP 
therapy with PUVA-treated BALB/c splenocytes. Splenocytes from C57BL/6->BALB/c mice having 




 PUVA-treated BALB/c splenocytes or having received 
PBS as control were investigated. ECP therapy was performed four times in weekly intervals starting 
from day 3 after BMT. Flow cytometry was performed with splenocytes from mice sacrificed when 
reaching a GvHD score ≥6 or at day 56 post BMT. Percentages of CD3
+ 
T cells (A), CD3
+







 Treg cells (C) amongst all splenocytes are shown. FACS analysis is 
based on 10-13 mice per group. The data are depicted as means ±SEM and were analyzed using the 
Mann Whitney U test. 
 




ECP therapy using PUVA-treated splenocytes obtained from C57BL/6 or BALB/c mice had 
not shown any therapeutic effects in a mouse model of aGvHD. Hence we asked whether 
ECP therapy with splenocytes of a third party donor mouse strain would be more successful. 
To address this question, C3H mice were used as splenocyte donors for ECP therapy after 
GvHD induction in C57BL/6->BALB/c mice. 
 
4.1.1.4.1. ECP therapy with splenocytes from C3H mice in an aGvHD mouse model 
Similar to the former experiments, aGvHD was induced by using C57BL/6 mice as BMT 
donors and BALB/c as recipient mice. For ECP therapy splenocytes were isolated from C3H 
mice and treated with 8-MOP and UV-A light. C57BL/6->BALB/c mice were weekly injected 
with PUVA-treated cells for four times starting at day 3 after BMT.  
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Fig. 10: ECP t herapy with splenocyte s of C3H origin re duces mortality, t he cli nica l aGvHD scor e, and weight l oss i n mouse model of aGvH D  
Fig. 10: ECP therapy with splenocytes of C3H origin reduces mortality, the clinical aGvHD 
score, and weight loss in mouse model of aGvHD. Irradiated BALB/c mice were transplanted with 
BM and T cells from C57BL/6 mice to induce aGvHD. For ECP therapy either 1x10
6
 (green line, n= 27) 
or 5x10
6
 (red line, n= 18) PUVA-treated splenocytes from C3H were injected four times in weekly 
intervals starting from day 3 after BMT. Control mice were simultaneously transplanted and treated 
with PBS (black line, n= 24). Kaplan Meier plots show the survival rates (A) and were analyzed with 




and the weight changes (C); statistical analysis by Mann Whitney U test. The data show means and 
are pooled from four independent experiments.  
 
C57BL/6->BALB/c mice injected with 1x106 PUVA-treated C3H splenocytes survived 
significantly longer (p=0.02) than control animals (Fig. 10A). Injection of 1x106 or 5x106 
PUVA-treated C3H leukocytes significantly decreased the clinical aGvHD scores (p<0.001) 
as compared to control mice (Fig. 10B). Furthermore, mice treated with 1x106 C3H 
splenocytes lost significantly less weight than control animals (Fig. 10C, p=0.02). In 
summary, ECP therapy using PUVA-treated splenocytes from C3H mice have a therapeutic 
potential in a mouse model of aGvHD.  
To perform flow cytometric analysis, treated C57BL/6->BALB/c mice were sacrificed when 
reaching a GvHD score ≥6 or at day 56 post BMT. Subsequently, the percentages of CD3+ T 
cells, CD4+ T cells, CD3+ CD8+ T cells, CD3- CD49b+ NK cells, and CD4+ CD25+ FoxP3+ Treg 
cells were determined in ECP-treated or control mice (Fig. 11). Mice which were treated with 
5x106 PUVA-treated splenocytes with C3H origin and survived the experiment had 
significantly less percentages of CD3+ T cells in comparison to those which died in the 
course of the experiment (Fig. 11 A; p=0.03).  
With the exception of PBS-injected mice, all other groups had higher percentages of CD3+ 
CD8+ T cells than mice which survived and had been injected with 5x106 PUVA-treated C3H 
splenocytes (Fig. 11C; p≤0.01).  
No relevant differences were found in percentages of CD3- CD49b+ NK cells, CD4+ T cells, 
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Fig. 11: FACS analysis of splenocytes fro m aGvHD mi ce after E CP therapy with cells of C3H origin  
 
Fig. 11: FACS analysis of splenocytes from 
aGvHD mice after ECP therapy with cells of 
C3H origin. ECP therapy was performed four 
times in weekly intervals starting from day 3 after 





 PUVA-treated cells 
obtained from C3H spleens. Control mice were 





















 Treg cells (E) amonst all splenocytes. 
FACS analysis is based on 24 mice treated with 
1x10
6
 cells, 17 mice injected with 5x10
6
 cells and 
22 control mice. Animals were sacrificed when 
reaching a clinical GvHD score of ≥6 or at day 56 





4.1.1.4.2. Analysis of the first peak in ECP therapy of aGvHD with splenocytes of C3H 
origin 
My previous experiments had revealed that C57BL/6->BALB/c mice treated with ECP 
therapy using cells derived from C3H strain showed a therapeutic effect. Based on these 
result it should be examined whether these ECP-treated mice also showed differences on 
the cytokine or cellular level compared to control mice at the highest peak of aGvHD. To this 
end, recipient mice were sacrificed at day 7 post BMT when clinical aGvHD were temporarily 
highest. Afterwards serum, splenocytes and, lymph nodes were isolated and analyzed by 
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Fig. 12: Analysis of splenocytes and serum from C57BL/6->BALB/c mice injected with PUVA-
treated cells of C3H origin. BALB/c mice received an allogeneic transplant from C57BL/6 donors. 
Three days post BMT one cohort of 15 C57BL/6->BALB/c mice was intravenously injected with 1x10
6
 
PUVA-treated splenocytes from C3H mice. Another group of 15 mice was injected simultaneously with 
PBS and served as a control. Seven days post BMT when the mice had reached the maximal clinical 
GvHD score they were sacrificed. Splenocytes were isolated and the percentages of either 
intracellular cytokines in T cells (A) or of several cellular subpopulations (B) were analyzed using flow 
cytometry. The serum was isolated using heart puncture and the concentrations of TGF beta 1 were 
determined by ELISA (C). The data show means ±SEM and were analyzed with the Mann Whitney U 
test.  
 
The analyses of intracellular cytokine expressions in T cells (CD3+ IFN-γ+, CD3+ IL-2+, CD3+ 
TNF-α+) showed no differences between ECP-treated and control mice (Fig. 12A) 
Furthermore, cellular composition of the splenocytes (Fig. 12B) and the lymph nodes (not 
shown) also showed no difference in the percentages of CD4+ CD25+ FoxP3+, CD4+, CD3+ 
CD8+ and, CD3- CD49+ cells between ECP-treated and control mice. The concentration of 
TGF-β1 in the serum at day 7 post BMT was similar in C57BL/6->BALB/c mice treated with 
ECP therapy and PBS-treated control mice (Fig. 12C). 
  
4.1.1.6. ECP therapy with cells activated in a mixed lymphocyte reaction  
4.1.1.6.1. Establishment of a mixed lymphocyte reaction in vitro 
The MLR was established in vitro by first determining the optimal cell density. To this end, 
MLRs were prepared at different cell densities and counted every day starting on day one 
after initiation of the culture. Generally, about 26-48 % of the cells died during the first four 
days of incubation. An MLR with 5x106 cells per ml was chosen as the optimal cell density 
because here the fewest cells died during incubation.  
Next, we wanted to determine the day when proliferation rate reached its peak. Before 
incubation, MLR cells were labeled with the cell proliferation dye eFlour and the proliferation 
rate was measured daily using flow cytometry. The highest proliferation rate was reached at 
day four after the setup of the MLR.  
As a final step of the establishment, the percentages of intracellular cytokines were analyzed 
by flow cytometry. At day six after MLR preparation the percentages of pro-inflammatory 
TNF-α+ and IFN-γ+ cells started to increase whereas the percentage of IL-2+ cells did not 
increase during MLR at all.   
Based on these results, the MLR was incubated at a density of 5x106 cells per ml for four 





4.1.1.6.2. ECP therapy with MLR cells from BALB/c and C57BL/6 donor mice 
After having established MLR in vitro (4.1.1.6.1.), the therapeutic impact of ECP therapy with 
MLR cells was examined in the mouse model of aGvHD. An MLR setup with splenocytes 
from BALB/c and C57BL/6 mice was prepared. Additionally, irradiated BALB/c splenocytes 
were incubated alone and served as control (BALB/c (xRay)). Following four days of 
incubation MLR cells and irradiated BALB/c cells were treated with 8-MOP/UV-A and were 
intravenously injected into allogeneic transplanted mice. One cohort of C57BL/6->BALB/c 
mice received PBS only and served as controls, a second cohort received 1x106 MLR cells 
and a third cohort 1x106 irradiated BALB/c cells (xRay). ECP therapy was performed four 
times in weekly intervals starting at day three after BMT. The therapeutic impact of PUVA-
treated MLR cells was measured by assessing the GvHD clinical score, weight loss and 
survival rates.  
As shown in Fig. 13, no difference in survival rate, the clinical GvHD score and, the weight 
loss could be found between mice treated with PUVA-treated MLR cells, irradiated BALB/c 
cells and control mice. Percentages of CD3+, CD3+CD8+, CD4+, CD4+ CD25+ FoxP3+ 
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Fig. 13: ECP t herapy of aGvHD using cells from M LR of C57 BL/6 a nd BALB/c origi n  
Fig. 13: ECP therapy of aGvHD using cells from MLR of C57BL/6 and BALB/c origin. Irradiated 
BALB/c mice received an allogeneic transplant containing BM and T cells of C57BL/6 mice to induce 
aGvHD. Treatment of C57BL/6->BALB/c mice was performed four times in weekly intervals and 
started day one after BMT. Two groups of transplanted mice served as controls and either received 
PBS (black line, n= 17) or 1x10
6
 radiated (30 Gy) PUVA-treated BALB/c splenocytes (red line, n= 18). 




MLR cells (green line, n= 20) which 
consisted of BALB/c leukocytes irradiated at 30Gy and co-cultured for four days with C57BL/6 
leukocytes in an incubator. The Kaplan-Meier plot shows the survival rate (A) and was analyzed using 
the log-rank test. The clinical GvHD score (B) and weight loss (C) were monitored daily and analyzed 
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Fig. 14: FACS analysis of aGvH D after ECP therapy with cells derived fr om an M LR 
Fig. 14: FACS analysis of aGvHD after ECP therapy with cells derived from an MLR. ECP 
therapy was performed four times in weekly intervals starting from day 3 after BMT by injecting 
C57BL/6->BALB/c mice with 1x10
6
 MLR cells. To this end, 5x10
6 
BALB/c irradiated splenocytes and 
5x10
6 
C57BL/6 splenocytes were prepared and co-cultured for four days. Control mice were treated 
with PBS or 1x10
6
 PUVA-treated irradiated (30 Gy) BALB/c splenocytes (Balb/c (xRay). The 
percentages of CD3
+ 
T cells (A), CD4
+ 











cells (D) amongst all splenocytes are shown. FACS analysis is based on 16 mice treated with 1x10
6
 
irradiated BALB/c splenocytes, 18 mice injected with 1x10
6 
MLR cells and 15 control mice receiving 
PBS. Animals were sacrificed when reaching a clinical GvHD score ≥6 or at day 56 post BMT. The 
data show the means +SEM. 
 





In earlier experiments PUVA-treated splenocytes from unmatched donor mice (C3H) were 
found exert a significant therapeutic effect in aGvHD (4.1.1.4.). Based on these results it was 
hypothesized that PUVA-treated MLR cells of C3H origin might also ameliorate aGvHD.  
To test this hypothesis MLR of splenocytes from BALB/c and C3H was prepared whereas 
BALB/c cells were irradiated. The MLR and the irradiated control BALB/c cells were 
incubated for four days. Following incubation, the MLR and the irradiated BALB/c cells were 
treated with 8-MOP and UV-A light and injected at a concentration of 1x106 into aGvHD 
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Fig. 15: ECP t herapy usi ng MLR cells of C3 H origi n in the m ouse model of acute GvHD  
Fig. 15: ECP therapy using MLR cells of C3H origin in the mouse model of acute GvHD. In the 
C57BL/6->BALB/c aGvHD mouse model ECP treatment was performed four times in weekly intervals 
starting at day 1 after BMT. Two cohorts of transplanted mice served as controls receiving either PBS 
(black line, n= 11) or 1x10
6
 irradiated (30 Gy) BALB/c PUVA-treated leukocytes (red line, n= 13). The 




MLR cells (green line, n= 14) consisting of 
C3H splenocytes co-cultured with 30Gy irradiated BALB/c leukocytes for four days. The Kaplan-Meier 
plot shows the survival rate (A) and was analyzed using the log-rank test. The clinical GvHD score (B) 
and the weight changes (C) were monitored daily and analyzed using the Mann Whitney U test. The 





Analysis of the survival rate, the clinical aGvHD score or weight loss did not reveal any 
differences between C57BL/6->BALB/c mice treated with MLR cells, irradiated BALB/c cells 
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Fig. 16: FACS analy sis of splenocyte s from aGvHD mice after ECP therapy wit h cell s derive d from a MLR of C3 H origi n  
Fig. 16: FACS analysis of splenocytes from aGvHD mice after ECP therapy with cells derived 
from a MLR of C3H origin. Allogeneic transplanted mice were treated with ECP therapy four times in 
weekly intervals starting day three after transplantation. ECP therapy was performed with PUVA-
treated MLR cells obtained in a similar manner as in Fig. 15. One cohort of C57BL/6->BALB/c mice 
was injected with 1x10
6
 MLR cells (n=10), a second cohort of mice was injected with PBS (n=8) and a 
third one with 1x10
6
 PUVA-treated irradiated (30 Gy) BALB/c splenocytes (Balb/c (xRay)) (n=11). The 
















 T cells (C) are 
shown. The data show the means ±SEM. 
 
The percentages of CD4+ T cells, CD4+ CD25+ FoxP3+ Treg cells and, CD3+ CD8+ T cells 
were undistinguishable between both control groups and mice which were injected with 
1x106 MLR cells from C3H/ BALB/c co-cultures (Fig. 16). 
 
4.1.1.8. Tracking ECP cells in the aGvHD mouse model 
Splenocytes incubated with 8-MOP and irradiated with UV-A light are known to undergo 
apoptosis. These apoptotic cells are believed to increase immune tolerance and mediate the 
therapeutic effect in ECP-treated human patients (Gatza et al., 2008). Therefore it was 
investigated for how long infused PUVA-treated, apoptotic cells could be tracked in spleen 
and lymph nodes of allogeneic C57BL/6->BALB/c mice. Transplanted mice were 
intravenously injected with splenocytes from CD45-congenic C57BL/6 donor mice 
(C57BL/6.SJL-Ptprca Pepcb/BoyJ) carrying the differential Ptrprcapan (CD45.1) leukocyte 
marker. In contrast, wildtype C57BL/6 donor mice expressed the Ptprcb (CD45.2) allele and 
could therefore be easily distinguished from CD45.1+ mice by flow cytometry using 
monoclonal antibodies.  
In the course of this study C57BL/6->BALB/c transplanted mice were injected with 15x106 
splenocytes from CD45.1+ donor mice. At 1, 24, 48, 72 and 96 hours after ECP therapy, the 
mice were sacrificed and analyzed concerning the number of CD45.1+ cells present in spleen 


































































Fig. 17: Tracking of PUVA-treated CD45.1
+
 splenocytes after ECP therapy of aGvHD mice. 
C57BL/6->BALB/c mice were injected once with 15x10
6





/BoyJ donor mice. At specific time points (1, 24, 48, 72, 98 hours) after 
ECP therapy the mice (n=3) were sacrificed. Absolute CD45.1
+
 splenocyte numbers [10
6
/spleen] are 
depicted in (A) whereas the percentages of CD45.1
+
 splenocytes and lymph node cells are shown in 
(B). The data are shown as means ±SEM.  
 
CD45.1+ splenocytes can be tracked up to 96 hours after ECP therapy (Fig. 17A). 24% 
splenocytes were found to be CD45.1 positive one hour after ECP therapy whereas 24 hours 
after ECP therapy only 5% splenocytes were CD45.1+ (Fig. 17B). In addition, lymph nodes 
were analyzed and one hour after ECP therapy 7% of all lymphocytes were found to be 
CD45.1 positive. In lymph nodes CD45.1 positive ECP cells were also tracked up to 96 hours 
after ECP therapy. 
 
4.2. Potential GvHD and ECP biomarkers in human patients receiving allogeneic BMT 
and cGvHD patients 
It is not only necessary to optimize ECP therapy but also to forsee whether a patient is going 
to suffer from GvHD or respond to ECP therapy. Biomarkers could help to predict both of 
them. To address this issue blood samples from patients were collected to examine the 
potency of potential biomarkers. 
 
4.2.1. Description of the employed blood donor groups 
To analyze potential GvHD and ECP biomarkers in allogeneic BMT and GvHD patients, 
blood samples were collected at defined time points. A scheme of the employed schedule of 
blood sampling is depicted below (Fig. 18). In total, 25 healthy blood donors served as 
controls and donated two blood samples with at least three months between the first and the 
second donation. Before each donation the health status of the blood donors was checked 
by a physician. To examine potential and already known GvHD biomarkers, 30 patients 
receiving allogeneic HSCT (HSCT patient) were selected to provide blood samples before 
transplantation (pre HSCT) and post engraftment. Blood samples from twelve GvHD patients 
were collected to find biomarkers for predicting response to ECP therapy. To this end, blood 
samples from GvHD patients were collected directly before the first ECP therapy cycle as 
well as three and six months afterwards. However due to severity of the disease some GvHD 







Fig. 18: Scheme of the bl ood sampling for the a nalysi s of GvHD a nd E CP bi omarkers  
Fig. 18: Scheme of the blood sampling for the analysis of GvHD and ECP biomarkers. 
 
4.2.2. Flow cytometric analysis of mononuclear cells 
MNCs were isolated from heparin blood by ficoll density centrifugation and were frozen at -
80°C. The samples of each patient or control subject were kept frozen until all samples at a 
defined time point were collected. Afterwards they were simultaneously analyzed by flow 
cytometry. On the one hand MNCs were analyzed in terms of percentage of all cells and on 
the other hand in terms of absolute numbers. 
 
4.2.2.1. Reference ranges for potential cellular biomarkers 
The reference values of peripheral blood subpopulations were analyzed in healthy adult 
blood donors. Percentages and absolute numbers of CD3+ T cells, CD19+ CD21- immature B 
cells, CD3+ CD4+ and CD3+ CD8+ T cells, and Lin1- CD11c+ HLA-DR+ mDCs as well as CD4+ 
CD25+ FoxP3+ Treg cells were analyzed by flow cytometry. 
 
Tab. 13: Reference ranges of potential cellular biomarkers in percentages amongst all MNCs. 
Peripheral blood samples were collected two times from healthy blood donors with at least three 
months difference between both donations. MNCs were drawn in S-Monovettes with the 
anticoagulants Lithium/ Heparin and isolated by using ficoll density centrifugation. After a freezing and 
thawing cycle, MNCs were analyzed by flow cytometry for the percentage of CD3
+



































[percentages amongst all MNCs] 
median 
2.5th - 97.5th 
 percentile min max 
CD3+ 25 64 48 – 80 48 80 
CD19+ CD21- 24 1.1 0.7 - 2.5 0.7 2.5 




CD3+ CD8+ 25 17 8.9 – 30 8.9 30 
CD4+ CD25+ FoxP3+ 24 2.5 1.4 – 5 1.4 5 
Lin1- CD11c+ HLA-DR+ 25 1.4 0.6 – 5.5 0.6 5.5 
Table 13 : Reference ranges of pote ntial ce llular biomarkers i n per centag es of all M NCs  
 
The reference ranges percentages from adult healthy blood donors were: CD3+ (48-80%), 
CD19+ CD21- (0.7-2.5%), CD3+ CD4+ (26-60%), CD3+ CD8+ (8.9-30%), and Lin1- CD11c+ 
HLA-DR+ (0.6-5.5%), and CD4+ CD25+ FoxP3+ (1.4-5%) (Tab. 13).  
In addition, the reference ranges absolute cell counts were: CD3+ (2080-8467), CD19+ CD21- 
(32-151), CD3+ CD4+ (530-3370), CD3+ CD8+ (96-939), and Lin1- CD11c+ HLA-DR+ (34-327), 
and CD4+ CD25+ FoxP3+ cells (34-327) (Tab. 14). 
 
Tab. 14: Reference values as absolute cell counts of potential cellular biomarkers. 
Peripheral blood from healthy blood donors were drawn in S-Monovettes with the anticoagulants 
Lithium/ Heparin. Blood samples were collected two times from with at least three months difference 
between both donations. MNCs were isolated by using ficoll density centrifugation. After a freezing 




























 Treg cells. n indicates the number of samples. Cell counts of 
the indicated cell populations are presented as medians, reference ranges were extracted from the 




[absolute cell count/µl] 
median 
2.5th - 97.5th 
 percentile min max 
CD3+ 21 3655 2080 – 8467 2080 8467 
CD19+ CD21- 18 63 32 – 151 32 151 
CD3+ CD4+ 21 1375 530 – 3370 530 3370 
CD3+ CD8+ 21 227 96 – 939 96 939 
CD4+ CD25+ FoxP3+ 21 140 64 – 485 64 485 
Lin1- CD11c+ HLA-DR+ 21 101 34 – 327 34 327 
Table 14 : Reference values a s absol ute cell counts of pote ntial cel lular biomarkers  
 
4.2.2.2. Comparison of both blood donations from control samples for differences in 
potential biomarkers 
As mentioned above, control subjects donated blood samples twice with a time difference of 
at least three months between donations. Differences in potential biomarker values between 
the first and the second donation were neither found in percentages amongst all MNCs nor in 





Tab.15: Comparison of two donation timepoints from control subjects. 
Blood samples were collected two times from healthy blood donors with at least three months 
difference between both donations. MNCs were isolated from peripheral blood drawn in S-Monovettes 
with the anticoagulants Lithium/ Heparin by using ficoll density centrifugation. After a freezing and 
thawing cycle, MNCs were analyzed by flow cytometry for the percentage or absolute numbers of 
CD3
+

























 Treg cells.. The data of controls were analyzed with 
the paired t test. The amounts (n) of control subjects are listed whereas p-values represent the 




amongst all MNCs 
absolute numbers 
 n p-value n p-value 
CD3+ 23 0.5 18 0.42 
CD19+ CD21- 22 0.9 18 0.55 
CD3+ CD4+ 22 0.23 18 0.78 
CD3+ CD8+ 23 0.2 18 0.26 
CD4+ CD25+ FoxP3+ 23 0.31 19 0.96 
Lin1- CD11c+ HLA-DR+ 22 0.71 18 >0.99 
Table 15 :Com parison of tw o donation timepoints from contr ol subje cts  
 
4.2.2.3. Comparison of cellular subpopulations as potential GvHD and ECP biomarkers 
4.2.2.3.1. T cells and immature B cells 
The absolute numbers and percentages of CD3+ T cells and CD19- CD21+ immature B were 
measured by flow cytometry. 
The percentage of CD3+ T cells amongst all MNCs (Fig. 19A) was increased in HSCT 
patients and ECP patients (p≤ 0.02) compared to controls.  
The absolute number of CD3+ T cells per µl peripheral blood (Fig. 20A) was reduced in 
HSCT patients compared to controls (p≤ 0.001). However, before ECP and three months 
after the first ECP therapy, GvHD patients showed increased T cells numbers compared to 
controls (p≤ 0.01). The absolute number of T cells was increased in GvHD patient compared 
to HSCT patients before HSCT (p≤ 0.017) and post engraftment (p≤ 0.001). 
The percentages of immature B cells amongst all MNCs (Fig. 19B) were increased in HSCT 
patients (p≤ 0.02) and GvHD patients before the first ECP therapy (p< 0.001) compared to 
the control group. Furthermore, the percentages of immature B cells were increased in HSCT 
patients post engraftment (p= 0.001) and GvHD patients before the first ECP therapy (p= 
0.0015) compared to the pre HSCT condition.  
The absolute number of immature B cells (Fig. 20B) was reduced before HSCT (p= 0.004) 
but increased before the first ECP therapy (p= 0.001) compared to controls. Significantly 




months after the first ECP therapy compared to HSCT patients before transplantation (p≤ 
0.01). Additionally, GvHD patients had significantly increased immature B cell numbers 

























































































































































































































































































































































































































































































































































































Fig. 19: Flow cyt ometric a nalysis of pote ntial GvH D and ECP biomarker s measure d in t he bl ood of HSCT a nd Gv HD patie nts  
Fig. 19: Flow cytometric analysis of potential GvHD and ECP biomarkers measured in the blood 
of HSCT and GvHD patients. Peripheral blood was collected from healthy blood donors (controls n= 




first ECP therapy (pre 1.ECP, n= 12) as well as three and six months afterwards (three (n= 6) & six 
(n= 3) months post 1.ECP). MNCs were isolated from peripheral blood drawn in S-Monovettes with the 
anticoagulants Lithium/ Heparin by using ficoll density centrifugation. After a freezing and thawing 
cycle, MNCs were analyzed for the percentage of CD3
+


























 Treg cells (F). MNCs were gated based on the FSC and the SSC. The box-and-
whisker plots represent the median with 25 to 75th percentile and min/max values. The data of 
controls were analyzed with the paired t test whereas all other data was analyzed with the Mann 
Whitney U test (ns (p≥0.05), * (p<0.05), ** (p≤0.01), *** (p≤0.001)). 
 
4.2.2.3.2. T cell subsets 
The different subsets of T cells were further analyzed in detail (Fig. 19 and 20). Compared to 
controls, the percentages of CD3+ CD4+ cells amongst all MNCs were increased in all HSCT 
patients (p≤ 0.01). GvHD patients had significantly lower percentages of CD3+ CD4+ T cells 
compared to controls (p≤ 0.003) and compared to HSCT patients (p≤ 0.004). The absolute 
numbers of CD3+ CD4+ T cells per µl were decreased in HSCT patients compared to healthy 
blood donors (p≤ 0.001).  
Furthermore, the percentages of CD3+ CD8+ T cells amongst all MNCs were significantly 
lower in HSCT patients post engraftment compared to controls (p≤ 0.001) and compared to 
HSCT patients before transplantation (Fig. 19; p< 0.001). However, after engraftment HSCT 
patients had lower percentages of CD3+ CD8+ T cells than GvHD patients before and after 
the first ECP therapy (p≤ 0.001). Additionally, the absolute numbers of CD3+ CD8+ T cells in 
HSCT patients post engraftment was reduced compared to controls (p< 0.001) and patients 
before HSCT (Fig. 20; p< 0.001). Furthermore, significantly more CD3+ CD8+ cells were 
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Fig. 20: Flow cyt ometric a nalysis of pote ntial GvH D and ECP biomarker s as absol ute cell number in the blood of HSCT and GvH D patie nts  
Fig. 20: Flow cytometric analysis of potential GvHD and ECP biomarkers as absolute cell 
number in the blood of HSCT and GvHD patients. Heparin blood was collected from healthy blood 




30) and after engraftment (post engraftment, n= 30) and GvHD patients before the first ECP therapy 
(pre 1.ECP, n= 12) as well as three and six months after the first ECP therapy (three (n= 6) & six (n= 
3) months post 1.ECP). Peripheral blood was collected in S-Monovettes with anticoagulants 
Lithium/Heparin and MNCs were isolated by using ficoll density centrifugation. After freezing and 
thawing MNCs the absolute cell number of CD3
+


























 Treg cells (F) per µl was analyzed using FACS. MNCs were gated in FSC and SSC. The box-
and-whisker plots represent the median, 25 to 75th percentile and min/max values. The data of 
controls were analyzed with paired t test whereas all other groups were analyzed with Mann Whitney 
U test (ns (p≥0.05), * (p<0.05), ** (p≤0.01), *** (p≤0.001)). 
 
4.2.2.3.3. Myeloid dendritic cells and regulatory T cells 
Fig. 19E shows the percentages of Lin1- CD11c+ HLA-DR+ (mDC) cells amongst all MNCs. 
The percentages of mDCs were increased in HSCT patients after engraftment compared to 
controls (p< 0.001) or HSCT patients before HSCT (p= 0.01). However, GvHD patients after 
ECP therapy had lower percentages of mDCs compared to patients before HSCT (p≤ 
0.0018) and after engraftment (p≤ 0.0230). Analysis of the absolute cell number of mDCs 
revealed that there were less mDCs in GvHD patients six months after the first ECP therapy 
compared to controls (p= 0.001), HSCT patients before transplantation (p= 0.025) and after 
engraftment (p= 0.0054).  
The percentages of CD4+ CD25+ FoxP3+ Treg cells are depicted in Fig. 19F and were 
increased before HSCT compared to controls (p< 0.0001). However, after engraftment (p= 
0.0086) and in ECP patients (p≤ 0.007) the percentages of Treg cells were lower than in 
HSCT patients before transplantation. With regard to the absolute cell numbers, Treg cells 
were reduced in HSCT patients after engraftment compared to controls (p≤ 0.001) and HSCT 
patients before transplantation (p< 0.001). In contrast, Treg cell numbers were elevated in 
GvHD patients before the first ECP therapy compared to patients after engraftment (p= 0.03).  
 
4.2.3. ELISA analyses of serum samples 
Serum concentrations of sIL-2R, sTNF-R and HGF were measured in healthy controls as 
well as in HSCT and cGvHD patients by ELISA.  
 
4.2.3.1. Cytokine levels in the serum of healthy subjects  
In serum of healthy control subjects several cytokines were analyzed for their reference 





Tab. 16: Reference ranges for serological cytokines.  
Serum samples were collected two times from healthy control subjects with at least three months 
difference between both donations. After a freezing and thawing cycle, serum was analyzed by ELISA 
for investigation cytokine levels.n indicates the amount of serum samples. Serological cytokine levels 
are presented as medians, reference ranges were extracted from the 2.5th to 97.5th percentile.The 





2.5th - 97.5th 
 percentile min max 
sIL-2R 25 6.1 4 - 8.6 4 8.6 
sTNF-R 24 1.1 0.1 - 3.5 0.1 3.5 
HGF 25 0.37 0.05 - 1.2 0.05 1.2 
Table 16 : Reference ranges for serol ogical cytoki nes  
 
4.2.3.2. Comparison of two blood donations from control subjects for the identification 
of differences in cytokine levels 
Peripheral blood samples were collected from healthy subjects at two timepoints with at least 
three months between both donations. It was investigated whether differences in cellular 
subpopulations occur between both donations. However, no differences in serological 
cytokine levels between both timepoints were found (Tab. 17). 
 
Tab. 17: Comparison of differences in serological cytokine levels between two timepoints of 
blood donations. Serum from healthy blood donors collected at different time points (1. donation (n= 
25) and 2. donation (n=24)). ELISA was performed for the quantitative detection sIL-2R, sTNF-R and 
HGF. n indicates the number of analyzed pairs of control subjects. The data of both timepoints of 




sIL-2R 24 0.49 
sTNF-R 23 0.37 
HGF 19 0.32 
Table 17 : Com parison of differe nce s in ser ologi cal cyt okine lev els betwee n two timepoints of blood donations  
 
4.2.3.3. Comparison of cellular subpopulations as potential GvHD and ECP biomarkers 
Compared to healthy controls, HSCT patients had elevated sIL-2R levels (p≤ 0.0199). Serum 
levels of sIL-2R were also increased in HSCT patients post engraftment compared to 
patients before HSCT (p= 0.0009). ECP patients had elevated sIL-2R levels compared to 
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Fig. 21: Analy sis of ser um sample s from HSCT and GvH D patie nts by E LISA for the detecti on of pote ntial GvHD a nd E CP biomarkers  
Fig. 21: Analysis of serum samples from HSCT and GvHD patients by ELISA for the detection 
of potential GvHD and ECP biomarkers. Peripheral blood samples were collected from patients 
before allogeneic HSCT (pre HSCT, n= 30) and after engraftment (post engraftment, n= 30). 
Furthermore, GvHD patients donated blood before the first ECP therapy (n= 12) and, three (n= 6) and 
six (n= 3) months afterwards. Serum from healthy blood donors collected at different time points (1. 
(n= 25) and 2. (n=24) donation) served as controls. ELISA was performed for the quantitative 
detection of human soluble interleukin-2 receptor alpha (sIL-2R) (A), soluble human tumor necrosis 
factor-receptor (sTNF-R) (B) and hepatocyte growth factor (HGF) (C). The box-and-whisker plots 
represent the median with 25 to 75th percentile and min/max values. The data of controls were 
analyzed with paired t test whereas all others by using Mann Whitney U test (ns (p≥0.05), * (p<0.05), 




Serum sTNF-R concentrations (Fig. 21B) were increased in HSCT patients (p< 0.0001) 
compared to healthy controls. sTNF-R values increased after engraftment compared to pre 
HSCT (p< 0.0001). Furthermore, GvHD patients showed elevated sTNF-R levels compared 
to controls (p≤ 0.004). sTNF-R serum levels were still elevated in GvHD patients before the 
first ECP therapy but seemed to decrease during ECP therapy. 
HGF concentrations in HSCT and ECP patients were elevated compared to healthy controls 
(p< 0.0001) (Fig. 21C). Additionally, HGF levels were increased after HSCT compared to 







5.1. ECP therapy of GvHD in mice using cells of different genetic origin 
In the course of this PhD project the therapeutic effect of ECP therapy on GvHD in vivo has 
been investigated. To this end, the C57BL/6->BALB/c total MHC mismatch mouse model of 
aGvHD known for its severe clinical GvHD symptoms and the poor survival rate has been 
used (Reddy et al., 2008). The protocol of ECP therapy was transferred from the clinical 
setting to the mouse model and was previously described in 2008 (Gatza et al., 2008). Here, 
Gatza and colleagues had treated a cohort of GvHD mice with ECP cells derived from 
another cohort of GvHD mice having undergone allogeneic transplantation. This protocol 
resembles the ECP procedure performed in the clinic and led to a therapeutic effect in a 
miHA mismatch mouse model of GvHD. In 2014, Budde and colleagues transferred this ECP 
setup in the C57BL/6->BALB/c mouse model of aGvHD and showed for the first time that it 
had a significant therapeutic effect when MHC class I and II molecules were mismatched 
(Budde et al., 2014). Furthermore, Capitini and co-workers had found in 2011 that ECP 
therapy with splenocytes from a wildtype BMT donor strain into MHC matched but miHA 
mismatch GvHD mouse model led to reduced weight loss. From this finding they concluded 
that the source of splenocytes for EPC treatment does not have to be same as the recipient 
itself, but instead can be from a third party donor (Capitini et al., 2011).  
Based on these previous findings, the aim of this PhD study was to modify ECP therapy in 
such a way that the exhausting apheresis procedure in GvHD patients could be replaced. 
Hence, a modified ECP setup using PUVA-treated splenocytes derived from different healthy 
donor strains was established and applied to C57BL/6->BALB/c transplanted mice suffering 
from aGvHD. Two different numbers of splenocytes were tested based on the idea that they 
should be close to or higher than clinical ECP protocols where 5-10% of the patients` 
circulating MNCs are treated with PUVA and reinfused (Flowers et al., 2008). ECP therapy 
was performed four times in weekly intervals since it is well known that ECP therapy has to 
be frequently repeated to achieve a positive outcome in patients (Greinix et al., 2006b).  
In the first modified ECP setup PUVA-treated splenocytes from the C57BL/6 mice were 
investigated. However, there was no therapeutic effect on the survival rate, the clinical score 
and weight loss. There was also no difference between mice injected with a low or a high 
dose of ECP cells. Noteworthy, our findings are in contrast to those by Capitini and 
colleagues who had found that ECP therapy with splenocytes derived from the BMT donor 
origin caused a reduced weight loss in a MHC match and miHA mismatch GvHD mouse 
model (Capitini et al., 2011). It should be mentioned that these authors did not show any 




PUVA-treated splenocytes sourced from wildtype BMT donor strain led to a therapeutic effect 
in Captini’s MHC matche and miHA mismatched whereas in our full MHC mismatched 
aGvHD mouse model there was no therapeutic effect. Subsequently, we tested our ECP 
setup in the B10D2->BALB/c mouse model of cGvHD which is based on a MHC matched but 
miHA mismatched graft. This model was used to investigate whether ECP therapy with 
splenocytes from the same strain as the BMT donor has a therapeutic effect on the course 
and severity of the disease. Interestingly, low dose ECP treatment showed a beneficial effect 
on cGvHD symptoms and weight loss compared to untreated allogeneic transplanted mice 
suffering cGvHD. The reduced weight loss is in concordance with the previously mentioned 
findings by Capitini and colleagues. PUVA treatment induces apoptosis within 24-48 hours 
after ECP treatment (Greinix et al., 2006b). APCs including dendritic cells and macrophages 
then begin to phagocytose these cells thereby inducing immune tolerance (Steinman et al., 
2000). Our findings thus indicate that apoptotic splenocytes that are genetically identical with 
the BMT donor strain may induce ECP-mediated tolerance in the cGvHD but not in the 
severe aGvHD mouse model.  
In a third approach it was analyzed whether ECP therapy with splenocytes derived from the 
same strain as the BMT recipient (BALB/c) would have a therapeutic effect on the course 
and clinical symptoms in the C57BL/6->BALB/c mouse model. Interestingly, compared to 
control mice the clinical score of ECP-treated mice was increased and additionally these 
mice even lost more weight. This suggests that aGvHD was unexpectedly aggravated in 
ECP-treated mice in this setup. 
As a next step C57BL/6->BALB/c mice received either low or high doses of PUVA-treated 
splenocytes from a third party strain (C3H). In comparison to control animals, ECP-treated 
mice showed a therapeutic effect on clinical scores and a reduced weight loss. In addition, 
mice treated with a low dose of apoptotic splenocytes had increased survival rates compared 
to controls. These findings are in concordance with those made by Bittencourt and co-
workers (Bittencourt et al., 2001). These authors had observed that no GvHD symptoms 
occurred when sublethally irradiated mice received a BM graft simultaneously with the 
apoptotic leukocytes regardless of the genetic source including a completely unrelated 
mouse strain. These findings were completed by data revealing that DCs pulsed with 
allogeneic apoptotic cells led to Treg cell expansion (da Costa et al., 2011). 
In summary, ECP therapy of aGvHD using apoptotic splenocytes from the BMT donor strain 
has no beneficial impact on the disease. Mice treated with apoptotic splenocytes derived 
from the recipient strain itself even struggled with aggravated clinical symptoms and lower 
survival rates. The only exception was when mice received PUVA-treated splenocytes from a 




thus shows that the therapeutic effect of ECP is dependent on the source of the PUVA-
treated splenocytes.  
 
5.2. Differential impact of ECP cells on splenocyte subpopulations in GvHD mice 
depending on their genetic background 
Although the mechanism of action of ECP therapy has not yet been fully understood, several 
investigators suggested that modulation of APCs and the induction of Treg cells may 
contribute to the immunoregulatory properties of ECP therapy (Greinix et al., 2006b; 
Marshall, 2006). It has been shown that DCs engulf apoptotic cells within 24 to 48 hours after 
treatment (Lamioni et al., 2005). Following uptake of apoptotic cells by DCs they develop a 
tolerogenic phenotype characterized by increased secretion of anti-inflammatory cytokines 
such as TGF-β1 (Fadok et al., 1998; Lucas et al., 2003). Subsequently tolerogenic DCs 
foster increased numbers and enhanced functions of Treg cells. Furthermore Tawara et al 
found that suppression of GvHD is based on the interaction between host APCs and donor 
Treg cells (Tawara et al., 2010).  
Since several T cell subpopulations are key mediators of GvHD on the one hand (CD4+; 
CD8+) and ECP therapy on the other hand (Treg cells) it should be studied whether T cell 
subpopulations in the different ECP setups were characteristically altered. Splenocytes were 
isolated from GvHD mice that were sacrificed either because they had reached an ethical 
end point during the experiment or after 56 days at the end of the experiment. Analysis of 
splenocytes was performed by flow cytometry.  
Treg cells were analyzed because they have been shown to be key players in modulating 
immune tolerance. In 2014, Budde et al. showed that the percentages of Treg cells in GvHD 
mice were significantly decreased compared to control mice which received syngeneic BMT 
without developing GvHD (Budde et al., 2014). In the study at hand, however there was no 
difference between control or ECP-treated mice no matter whether GvHD mice received 
splenocytes derived from C57BL/6, BALB/c or C3H mice. It is noteworthy that this 
observation is in contrast to the findings of Gatza and colleagues who had found that the 
numbers of Treg cells in thymus and spleen were increased and that the beneficial effect of 
ECP therapy was lost when mice additionally received an anti-CD25 antibody for depletion of 
Treg cells (Gatza et al., 2008). It should also be mentioned that Treg cell numbers were 
found to be increased in ECP-treated patients compared to baseline (Biagi et al., 2007; 
Tsirigotis et al., 2012).  
CD4+ T cells were analyzed because they play an important role in the pathogenesis of 




treated aGvHD or cGvHD mice were found. Furthermore there was also no difference 
between ECP-treated mice that responded to the therapy compared to those which did not 
survive. In contrast to our results ECP-treated cGvHD patients responding to this therapy 
were found to have increased numbers of circulating CD4+ T cells (Akhtari et al., 2010). 
Besides Treg cells and Th cells, also the percentages of CD3+ T cells in spleen were 
analyzed in the aGvHD mouse model. Those mice which received a high dose of PUVA-
treated splenocytes from an allogeneic third party donor strain and survived the experiment 
showed decreased percentages of CD3+ T cells compared to those mice that had to be 
sacrificed for ethical reasons. This result corresponds to the higher survival rates of mice 
treated with ECP cells from a third party donor (C3H). aGvHD mice injected with PUVA-
treated splenocytes from the BMT donor (C57BL/6) or recipient strain (BALB/c) showed no 
differences in the percentages of CD3+ T cells compared to control mice. Mice treated with 
high-dose PUVA-treated splenocytes showed less clinical GvHD symptoms than controls, 
and mice that responded to therapy had reduced percentages of CD3+ T cells in spleens 
compared to non responding mice. This observation is in accordance with the finding that 
CD3+ T cell numbers are increased in GvHD patients (Abrahamsen et al., 2005), and that 
administration of an anti-CD3 antibody was paralleled by an improvement of clinical GVHD 
symptoms. Thus, the less severity of GvHD correlates with the percentages of CD3+ T cells 
(Anasetti et al., 1992). 
In the model receiving third party ECP cells, the percentages of CD3- CD49+ NK cells had 
been found to be decreased in responder mice which received the high dose compared to 
those injected with low dose PUVA-treated splenocytes. NK cells belong to the innate 
immune system and have the capacity to kill target cells lacking MHC class I molecule and 
secrete cytokines. With regards to GvHD NK cells are able to reduce disease severity by 
inhibiting and lysing autologous donor T cells which had previously been activated by the 
initiation of GvHD (Olson et al., 2010).  
Finally, percentages of CD3+ CD8+ T cells were analyzed in the aGvHD mouse model treated 
with ECP cells from a third party donor strain. Compared to controls and low dose ECP-
treated mice there were significantly less CD3+ CD8+ T cells in high dose ECP-treated mice 
which survived the whole duration of the experiment. 
Another aim of this study was to find out whether ECP therapy altered cytokine production by 
T cells (TGF-β1; CD3+ IFN-γ+; CD3+ IL-2+; CD3+ TNF-α+) or the frequency of various 
lymphocyte subpopulations (CD3+ CD8+; CD3- CD49+; CD4+; CD4+ CD25+ FoxP3+) at day 7 
after BMT corresponds to the first peak of severe GvHD symptoms. The cytokine TGF-β1 is 




cells (Sakaguchi et al., 2008), and intravenous infusion of apoptotic cells causes an 
expansion of Treg cells in a TGF-β1 dependent manner (Kleinclauss et al., 2006). IL-2, IFN-
γ, and TNF-α are pro-inflammatory cytokines produced by T cells. Hence, analysis of these 
mediators could provide insight whether ECP therapy fostered T cell immunity or rather 
immune suppression. Analysis of splenocytes revealed that there were no differences 
between ECP-treated mice and controls in any of these parameters. This result coincides 
with the previously mentioned investigations that steady-state administration of apoptotic 
cells was needed to induce immune tolerance. Therefore it can not be excluded that 
differences could be observed if a similar analysis would be performed at several timepoints 
during ECP therapy.  
Another study was also conducted to verify for how long injected PUVA-treated splenocytes 
were detectable in the aGvHD mouse model. This was achieved by using ECP cells derived 
from CD45.1-congenic C57BL/6 mice allowing to easily detect the transferred cells with 
antibodies by flow cytometry. Spleen and lymph nodes of ECP-treated GvHD mice were 
studied at different time points based on the assumption that in these locations host APC 
population remove apoptotic cells (Morelli et al., 2003). Interestingly, more than 20% of 
CD45+ cells in the spleen disappeared within 24 hours, possibly due to the fact that APCs 
engulf apoptotic cells very fast. Previously, Wang and colleagues had monitored the transfer 
of apoptotic lymphocytes labeled by CFSE and found that the majority of labeled cells 
accumulates in the liver of mice and that those cells disappeared within twelve hours (Wang 
et al., 2006).  
 
5.3. Effects of pre-activated ECP cells on the course and severity of GvHD in a mouse 
model 
Edelson hypothesized that apoptotic cells have to be alloreactive to be effective in an ECP 
procedure (Edelson, 2014). In agreement with this hypothesis mice suffering aGvHD showed 
a therapeutic effect when being injected with EPC-treated splenocytes from another cohort of 
aGvHD suffering mice (Budde et al., 2014).  
In addition, Hannani et al. showed that activated T cells die more rapidly than resting T cells 
after ECP therapy (Hannani et al., 2010). This indicates that only pre-activated T cells may 
undergo cell death during the first hours after ECP therapy. Consequently, the time between 
induction of APCs and actual phagocytosis of dying T cells would be shortened. 
Based on these observations the impact of alloreactive ECP cells should be investigated in 
the mouse model of aGvHD by activating lymphocytes in vitro using MLR before applying 




mice were activated by irradiated BALB/c splenocytes followed by PUVA treatment and 
transfer into GvHD mice. No differences in the survival rate, the clinical GvHD score or 
weight loss between control mice or ECP-treated mice were observed. In a second setup 
splenocytes from C3H instead of C57BL/6 were activated by irradiated BALB/c splenocytes 
and tested for the therapeutic efficacy. However, also here no differences regarding survival 
rate, clinical score or weight loss were found between controls and ECP-treated mice. There 
were also no differences in the percentages of CD3+, CD4+, CD4+ CD25+ FoxP3+ , and CD3+ 
CD8+ T cells between control and ECP-treated mice found. These findings indicate that the 
MLR cells were either sufficiently alloreactive or that alloreactivity is not necessary for 
apoptotic T cells to generate a tolerogenic immune status. 
 
5.4. Search for novel GvHD and ECP biomarkers 
Biomarkers serve as indicators of normal biologic or pathogenic processes or, of response to 
treatment modalities. With regard to GvHD, biomarkers should allow assessing the risk of 
developing GvHD after HSCT, and the prognosis of disease. Several types of biomarkers 
have already been investigated as potential GvHD markers. However, biomarkers predicting 
the response to ECP therapy are also highly needed in view of the logistic challenges, the 
high costs, and the exhausting apheresis procedure. The aim of our group is therefore to 
identify biomarkers as indicators of the responsiveness to ECP treatment. Thereby 
physicians might be able to subdivide patients into low-response and high-response groups 
and thereby predict the patients’ response to ECP therapy. In the course of this study several 
putative GvHD and ECP biomarkers have been tested, all of which were associated with 
GvHD in previous studies. 
As a first step whole blood was collected from several healthy blood donors for determining 
the reference values of selected putative biomarkers. Subsequently, potential cellular and 
cytokine biomarkers were measured and reference values calculated. When comparing 
reference values of this study with those of other investigators, it has to be taken into account 
that differences can be due to blood sample preparation techniques (Vuckovic et al., 2004). 
Furthermore, potential biomarkers were also studied in the blood and serum from healthy 
controls, HSCT and cGvHD patients. 
 
5.4.1. Suitability of cellular subpopulations as potential biomarkers 
The development of GvHD goes along with an elevation in the proportion of CD3+ CD4+ CD8+ 
cells within the first 7-21 days post-transplant (Brinkman et al., 2007). Furthermore increased 




cGvHD whereas percentages of naïve CD8+ T cells were decreased (D’Asaro et al., 2006; 
Yamashita et al., 2004). In contrast to cGvHD, August and coworkers found that CD8+ T cells 
were increased in patients suffering aGvHD (August et al., 2011).  
Based on all the aforementioned findings and the fact that T cell subsets are associated with 
the development of GvHD their analysis was in focus of this study. The reference value for 
the frequency of CD3+ T cells in peripheral blood was 48-80% whereas absolute cells count 
had a median of 3655 cells per µl. The percentages of CD3+ T cells amongst all MNCs were 
increased in HSCT before transplantation and after engraftment as well as in cGvHD patients 
before and during ECP treatment. We found a decrease of total CD3+ cells in patients before 
and after transplantation which can be based on the common occurrence of leukopenia. 
Furthermore, increased CD3+ cells were found in cGvHD patients before and three months 
after initiation of ECP therapy. Groups like Abrahmsen and coworkers also showed that 
cGvHD was associated with higher counts of CD3+ T cells compared to those patients with 
no GvHD (Abrahamsen et al., 2005). 
CD3+ CD4+ T cells in peripheral blood from healthy control subjects had a reference range of 
530-3370 cells per µl and 26-60% amongst all MNCs. In our study, CD3+ CD4+ T cells counts 
were decreased in HSCT patients before and after transplantation. The large range of the 
CD3+ CD4+ values indicates that HSCT patients could be differentiated into two groups. It 
would be possible that these two groups differ in the incidence and severity of GvHD and 
therefore have to be studied separately in the future. Furthermore, we found that the 
percentages of CD3+ CD4+ T cell were increased in HSCT patients but decreased in cGvHD 
patients compared to HSCT patients and controls. However during ECP treatment the 
frequency of this subpopulation stays on this plateau. 
The reference values of the CD3+ CD8+ T cell subset in healthy controls were 8.9-30% or 96-
939 cells/µl. In our study, HSCT patients analyzed shortly after engraftment showed 
decreased frequencies and cell counts of CD3+ CD8+ T cells compared to controls, whereas 
during ECP therapy these values increased in cGvHD patients. This observation is in 
accordance with the findings of Abrahamsen because these authors found that cell counts of 
CD8+ T cells were increased in cGvHD patients (Abrahamsen et al., 2005). 
The reference values of the percentages of Treg cells measured in this study are in 
agreement with those described by Watanbe and colleagues (Watanabe et al., 2011). 
Namely, healthy subjects and cGvHD patients had a median of 2% Treg cells in peripheral 
blood. In contrast, aGvHD patients had around 5% Treg cells. Watanbe et al. further reported 
that 6-25 Treg cell/µl were the normal range in healthy subjects. This in fact is different to the 




Interestingly, Watanbe and colleagues also described that compared to healthy control 
subjects, cGvHD patients had 3-fold higher Treg cell counts whereas this values was similar 
in aGvHD patients and healthy controls. In our study, the percentages of Treg cells in 
patients after engraftment and in cGvHD were not altered compared to healthy controls and 
did also not change three and six months after initiation of ECP treatment. It is noteworthy 
that this result is in contrast to Di Biaso’s findings showing that ECP-responding patients 
have significantly increased numbers of circulating Treg cells (Di Biaso et al., 2009). Treg cell 
counts in HSCT patients after engraftment were reduced compared to those patients before 
allogeneic HSCT. cGvHD patients seem to have almost unaltered Treg cell counts compared 
to controls. 
CD21- B cells were previously found to be increased in rheumatoid arthritis and common 
variable immunodeficiency (Isnardi et al., 2010). In our study the reference values for these 
immature B cells were 0.6-5.5% amongst all MNCs and 34-327 cells/µl. When compared to 
healthy controls cGvHD patients had elevated numbers and percentages of immature CD21- 
B cells. This result is in agreement with those of Greinix and colleagues (Greinix et al., 2008). 
Interestingly, Kuzmina and coworkers found that GvHD patients had about 22% immature B 
cells in peripheral blood before ECP therapy was applied. They also reported that patients 
responding to ECP therapy had decreased percentages (~5%) of immature B cells whereas 
ECP non responders did not have increased percentages of the same (Kuzmina et al., 
2009). 
Reference values of mDCs were 0.6-5.5% and 34-327 cells/µl. Heinze and colleagues had 
previously measured reference ranges from children and found that mDC values strongly 
correlated with age (Heinze et al., 2013). Compared to healthy controls in this study, 
percentages of mDCs amongst all MNCs were increased in engrafted patients whereas 
percentages of mDCs were decreased in cGvHD patients six months after their first ECP 
therapy. The mDC cell counts in cGvHD patients six months after the initiation of ECP 
therapy were also decreased compared to controls. According to these results, mDCs should 
be investigated in more patients in order to determine if this is a potential biomarker for 
predicting responsiveness to ECP therapy. 
 
5.4.2. Potential cytokine biomarker 
In addition to cellular biomarkers in peripheral blood, cytokine levels were studied in the 
serum from healthy controls, HSCT and cGvHD patients. Paczesny and colleagues had 
suggested that IL-2Rα, TNF-R1, HGF, and IL-8 might be most suitable for predicting the 




considered as promising biomarkers also for cGvHD patients and may also allow predicting 
the responsiveness to ECP therapy. 
sIL-2R is a well known marker of T cell activation and suppression of donor T cell responses 
in GvHD prophylaxis. In serum the measured reference range of sIL-2R levels is 
approximatelly 6 ng/µl. Consistent with the results of Kami and co-workers, serum sIL-2R 
levels were elevated in HSCT and aGvHD patients in our study. Kami and colleagues also 
found a correlation between the grade of aGvHD and sIL-2R levels (Kami et al., 2000). In our 
study the levels were elevated during ECP therapy but did not decrease. 
In this study, serum levels of sTNF-R were found to be increased in patients suffering from a 
hematopoietic disease whereas these levels increased after allogeneic HSCT. cGvHD 
patients still had elevated levels of sTNF-R whereas during ECP therapy these levels 
seemed to go back to baseline. As known from literature sTNF-R is mostly released from 
TNF-α-secreting monocytes. Animals models showed that the inflammatory cytokine TNF-α 
is a mediator of GvHD (Reddy and Ferrara, 2003). Furthermore when a soluble inhibitor of 
TNF-α was added to steroids as first-line treatment of GvHD high percentages of response 
rates were observed (Levine et al., 2008). 
It was discovered that HGF is secreted by target organs which have been impaired by GvHD 
(Paczesny et .al., 2009b). Therefore HGF was discussed as potential biomarker for GvHD. 
Okamoto and colleagues found that 18 normal persons had HGF levels of approximately 4 
ng/ml in their serum (Okamoto et al., 2001). In contrast to their results, 25 healthy blood 
donors measured in the course of this study had around 0.4 ng/ml. In addition, HGF levels 
were elevated in patients before transplantation and further increased after engraftment in 
our study. In the serum of cGvHD patients involved in this study, higher HGF levels were 
found compared to healthy controls. Also in serum of aGvHD patients higher HGF levels 
were found and additionally higher levels of HGF were correlated with the grade of aGvHD 
(Okamoto et al., 2001).  
To sum up, all potential biomarkers tested were found to be associated with the 
pathophysiology of GvHD. The question whether these putative markers could also predict 
the responsiveness of ECP therapy remains unclear. However this question can probably be 
solved in the future when the number of samples from GvHD patients is increased, and most 
importantly when it is clear which patients responded to the ECP treatment.   
 




The results obtained in ECP-treated mouse models of GvHD feed the hope that it might be 
possible that the exhausting apheresis procedure is exchanged by leukocytes derived from 
third party donors. However, when donor-derived leukocytes were used for ECP therapy in 
mouse models of cGvHD and aGvHD not all tested ECP-treated leukocytes had an effect on 
the course and severity of GvHD. The most obvious explanation for the observed differences 
are the disparate MHC antigens of the mouse strains used as donors for allogeneic grafts 
and the isolation of leukocytes for ECP treatment. Mouse strains used as donors for ECP 
were BALB/c (H-2Dd), C57BL/6 (H-2Db), and C3H (H-D2k), whereas B10.D2 (H-2Dd) or 
C57BL/6 were used as donors for the induction of cGvHD or aGvHD. BALB/c served as 
recipients of allogeneic transplantation in all cases. As a next step to further prove the 
efficacy of third party donors as a source of leukocytes for ECP treatment several other 
mouse strains should be tested as donors for ECP cells. In the context of the already used 
cGvHD or aGvHD mouse models several mouse strains could serve as ECP cell donors, 
including DBA/1 (H-2Dq), BDP/J (H-D2p), or I/LnJ (H-2Dj). If these third party donors would 
also show a therapeutic effect on the course and severity of GvHD one could think about 
applying this modified ECP therapy in a clinical study.  
Regarding the search for potential biomarker for predicting the responsiveness of ECP 
therapy further evaluation is necessary. Based on the fact that the collection of many blood 
samples from HSCT patients was completed only a few months ago we are not yet 
completely informed about the health status of every single patient enrolled in this study. This 
information, however, is of great importance since based on these informations patients 
could be divided into several subgroups to further evaluate our flow cytometric and 
serological data. The ability to divide patients into different groups would probably reduce the 
observed broad distribution of cellular values. In addition the amount of blood samples from 
cGvHD patients with ECP treatment needs to be increased to assess whether ECP-treated 
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